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ABSTRACT  
   
There is a need to reinvent evidence-based interventions (EBIs) for pediatric 
anxiety problems to better address the demands of real-word service delivery settings and 
achieve public health impact. The time- and resource-intensive nature of most EBIs for 
youth anxiety has frequently been noted as a barrier to the utilization of EBIs in 
community settings, leading to increased attention towards exploring the viability of 
briefer, more accessible protocols. Principally, this research reports between-group effect 
sizes from brief-interventions targeting pediatric anxiety and classifies each as well-
established, probably efficacious, possibly efficacious, experimental, or questionable. 
brief interventions yielded an overall mean effect size of 0.19 on pediatric anxiety 
outcomes from pre to post. Effect sizes varied significantly by level of intervention: Pre 
to post-intervention effects were strongest for brief-treatments (0.35), followed by brief-
targeted prevention (0.22), and weakest for brief-universal prevention (0.09). No 
participant or other intervention characteristic emerged as significant moderators of effect 
sizes. In terms of standard of evidence, one brief intervention is well-established, and five 
are probably efficacious, with most drawing on cognitive and behavioral change 
procedures and/or family systems models. At this juncture, the minimal intervention 
needed for clinical change in pediatric anxiety points to in-vivo exposures for specific 
phobias (~3 hours), cognitive-behavioral therapy (CBT) with social skills training (~3 
hours), and CBT based parent training (~6 hours, eight digital modules with clinician 
support). This research concludes with a discussion on limitations to available brief EBIs, 
practice guidelines, and future research needed to capitalize on the viability of briefer 
protocols in enhancing access to, and impact of, evidence-based care in the real-world.  
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CHAPTER 1 
INTRODUCTION 
The past three decades of research show that non-pharmacological interventions 
are efficacious in the treatment and prevention of pediatric anxiety; however, few 
interventions are having public health impact (National Academies of Sciences, 
Engineering, and Medicine, 2017). There are several possible reasons for this need-to-
access gap, including complex organizational and systems-level factors (e.g., 
organizational culture, implementation climate; readiness for change; Aarons, Moullin, & 
Ehrhart, 2018; Aarons & Sawitzky, 2006; Powell et al., 2015). However, many could be 
related to the structural design features of most evidence-based interventions (e.g., 
number, length, and frequency of sessions, type of provider training and supervision. A 
number of studies have highlighted a misfit between the structure of evidence-based 
interventions for pediatric anxiety and the realities of youth, families, and community 
care providers. For instance, Ringle et al. (2015), Reid et al. (2017), and Salloum et al. 
(2016) indicated that: (a) the number and length of sessions is often incompatible with 
child and family schedules, (b) insurance inconsistently covers the cost of EBIs and out-
of-pocket expenses are high, (c) protocols are multi-component and complex, and (d) 
implementation often requires extensive provider and/or organizational resources (e.g., 
training, supervision, funding). And, because implementation of EBIs is often resource-
intensive, these programs are increasingly limited to organizations in urban and higher 
resource areas, making them inconsistently accessible to youth and families, especially in 
rural or low-resource communities (Yancey, Glenn, Ford, & Bell-Lewis, 2018). As a 
result, when an evidence-based psychosocial intervention reaches the community, 
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provider-driven adaptations occur (e.g., as much as two-thirds of the intervention is 
adapted for real-word delivery; Rhoades, Bumbarger, & Moore, 2012), which probably 
compromise clinical outcomes (e.g., from deviations in protocol fidelity; Berkel et al., 
2011).  
To support evidence-based services in reaching the intended public health impact, 
a second wave of efficacy and effectiveness research has emerged and is focused on 
‘reinventing’ evidence-based interventions (EBIs). More specifically, Brownson, Colditz, 
and Proctor (2018) defined reinvention as the modification of EBIs to maximize fit 
between interventions, the realities of delivery organizations, and the needs of end-users 
(e.g., service providers, youth, parents). One way in which EBIs could be reinvented is 
via a shift towards briefer, more streamlined protocols based on emerging empirical data 
indicating that longer treatments do not necessarily equate to superior clinical outcomes 
in pediatric populations, including those for anxiety. For instance, in a meta-analysis of 
447 RCTs of psychological interventions targeting youth mental health problems 
(including 143 for anxiety), it was found that the magnitude of intervention effects was 
unrelated to the number of intervention sessions (Weisz et al., 2017). It was further 
reported that the number of treatment weeks was significantly and negatively related to 
the magnitude of ES at posttest, suggesting that as the total duration of intervention 
increases, intervention effects diminish.  
With regards to pediatric anxiety specifically, Ost and Ollendick (2017) found 
initial support for brief, intensive, and concentrated protocols (referred to as brief 
hereafter) for the treatment of pediatric phobias. For pediatric anxiety, Ost and Ollendick 
only found four studies and thus cautioned against making strong conclusions regarding 
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efficacy or effectiveness of these brief protocols. Here, Ost and Ollendick operationalized 
interventions as brief if the intervention was at least 50% fewer total sessions versus 
standard treatments, intensive if the number of sessions and intervention duration was 
reduced versus standard treatment (e.g., one, 180 minute session treatment for specific 
phobia), and concentrated if the intervention had a standard number of sessions, but 
sessions were delivered in a shorter time period (e.g., 12 sessions of CBT delivered in 6 
weeks). Using data corresponding to 23 RCTs, brief, intensive, and concentrated 
interventions produced a large overall within-group treatment effect sizes on anxiety 
outcomes at post-treatment (g = 1.50) and follow-up (M = 5.6 months; g = 1.53). 
Interestingly, overall effect sizes from the reinvented EBIs included in the Ost and 
Ollendick meta-analysis were more similar than different to those derived from typical 
length EBIs (e.g., 12 or more sessions). As such, reinvented EBIs that are briefer and 
more streamlined than typical length protocols might offer unique opportunities to 
positively affect population-level health outcomes. 
This reinvention of typical EBIs into brief EBIs raises questions about the idea 
that there might be a minimal intervention needed for change (Glasgow et al., 2014). 
Such minimal interventions are intended to offer the smallest program dosage and 
intensity that can be delivered by an implementer with minimal expertise and resource set 
to achieve positive clinical outcomes. Ideally, these minimal interventions are theorized 
to work best by including only the strongest EBI elements, while considering design 
features that yield consumer friendly protocols (e.g., highly compatible with user needs, 
low application complexity). More specifically, and applied to EBIs for youth anxiety, a 
minimal intervention needed for change would include a minimal number of theoretical 
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and empirically based clinical elements (e.g., cognitive restructuring, exposure, 
relaxation) and incorporate the minimum intervention duration, or dosage, required to 
produce meaningful change. This minimal intervention would utilize the least trained and 
least expensive provider that can implement the intervention with quality and fidelity. In 
theory, this approach could provide a blueprint to guide EBI reinvention, potentially 
leading to briefer, more streamlined protocols for pediatric anxiety that are less costly and 
resource-intensive, more scalable and user-friendly, and better positioned for large-scale 
dissemination and implementation in real-world settings. The need for briefer, more 
streamlined interventions is consistent with recommendations established by frameworks 
in the dissemination and implementation science field. For instance, the Knowledge to 
Action framework, established by the Centers for Disease Control and Prevention 
(Wilson et al. 2011), emphasizes the need for translating evidence-based programs into 
more streamlined and consumer accessible versions to accelerate dissemination and 
implementation efforts. Likewise, the ‘disruptive innovation’ perspective outlined by 
Rotheram-Borus, Swendeman, and Chorpita (2012) recommends redesigning 
interventions to focus only on their most robust clinical features and meet the essential 
needs for the majority of consumers in order to enhance the public health impact of EBIs. 
Relatedly, the diffusion of innovations framework (Rogers, 2002; 2010) suggests 
innovations (like an EBI) are more likely to be adopted, and at a quicker rate, if they have 
high compatible with consumer needs and low application complexity. Similarly, the RE-
AIM model suggests that EBIs are more likely to be delivered at broader scale and with 
higher quality under real-world conditions, if they are minimally intensive and include 
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only the elements necessary for implementation and clinical improvement (Harden et al., 
2018; Kessler, Purcell, Glasgow, Kelsges, Benkeser, & Peak, 2012).  
Since the initial work of Ost and Ollendick (2017), new randomized controlled 
trials (RCTs) targeting pediatric anxiety via brief, non-pharmacological, interventions 
have been published. In addition, about one third of these brief interventions deviate from 
cognitive and behavioral therapy theory, which is a positive step toward intervention 
innovation in pediatric anxiety. Armed with this knowledge, the time is ripe for shedding 
new light on progress made toward determining if there might be a viable minimal 
intervention for clinical change in the pediatric anxiety area. The focus on pediatric 
anxiety is important for several reasons. First, anxiety disorders are among the most 
prevalent psychiatric problems in youth, with rates ranging from 5% to 12% in children 
and as high as 31% in adolescents (Merikangas et al., 2010). Second, anxiety disorders 
are associated with impaired functioning across a number of areas, including academic 
achievement, social competence, and self-esteem (e.g., Ezpeleta, Keeler, Erkanli, 
Costello, & Angold, 2001). Third, without intervention, anxiety disorders often persist 
into adulthood and for some youth, are prospectively linked to later negative sequela, 
including clinical depression, suicidal ideation, conduct problems, and substance use 
disorders (Cummings, Caporino, & Kendall, 2013). Fourth, pediatric anxiety disorders 
carry a significant societal cost, exceeding $17 billion per year, largely due to healthcare 
expenditures, school absenteeism, and lost productivity due to parents or primary 
caregivers missing work (e.g., therapy appointments, staying home with the child, 
medical visits) (Bodden, Dirksen, & Bogels, 2008; Chisholm et al., 2016). In this context, 
the relative financial costs of youth anxiety problems, combining absolute costs with 
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prevalence, are similar to conduct disorders and higher than those of autism spectrum 
disorders (Bui et al., 2017; Kilian, Losert, Park, McDaid, & Knapp, 2010). 
In response to the public health impact of pediatric anxiety, substantial efforts 
have focused on developing, evaluating, and isolating several evidence-based 
interventions (EBIs) to treat these disorders. In 1998, Ollendick and King published the 
initial evidence-based status report of psychosocial interventions for phobic and anxiety 
disorders. This report largely focused on the classification of psychosocial interventions 
using criteria developed by Chambless and colleagues (Chambless et al., 1996, 1998; 
Chambless & Hollon, 1998) as part of a task force effort promoting the classification of 
treatments for disseminating interventions to practitioners, psychology training programs, 
consumers, and third-party payers (American Psychological Association, 1993). With 
treatment research focused on pediatric phobic and anxiety disorders using systematic 
diagnostic criteria just emerging, Ollendick and King identified just four randomized 
controlled trials (RCTs), relying mostly on single group treatment and case design studies 
with non-clinic-referred and undiagnosed youth. Based on their review, Ollendick and 
King concluded that imaginal and in vivo exposures and cognitive-behavioral procedures 
(with and without parents) were probably efficacious for childhood phobias and 
childhood anxiety disorders, respectively. A decade later, Silverman, Pina, and 
Viswesvaren (2008) published their seminal review and meta-analysis, updating the 
evidence-based status of psychosocial interventions for phobic and anxiety disorders in 
children and adolescents. Across 32 randomized trials, it was found that no treatment met 
the highest standard of evidence (i.e., well-established), but several treatment programs 
were identified as probably efficacious or possibly efficacious, with many drawing on 
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cognitive and behavioral therapy (CBT), exposure-based approaches, and family therapy 
models.  
Recently, Higa-McMillan, Francis, Rith-Najarian, and Chorpita (2016) published 
an update to Silverman et al. (2008) that focused on examining progress made in securing 
psychological interventions for youth anxiety. In addition to expanding study selection 
criteria to include prevention and early intervention trials, Higa-McMillan et al. 
aggregated treatments by approach (e.g., exposure, CBT, parent training) rather than 
“brand name” (e.g., Coping Cat). More specifically, Higa-McMillan and colleagues used 
practice element profiling based on the work of Chorpita and Daleiden (2009) to identify 
the specific clinical elements (e.g., psychoeducation, relaxation, exposure) of the 
treatment protocols evaluated in each study. Then, to identify the ‘treatment families’ to 
be evaluated and classified using the Southam-Gerow and Prinstein (2014) guidelines, 
treatments were aggregated when they shared a majority of therapeutic elements with 
comparable theoretical foundations, while separating treatments with principally different 
theoretical underpinnings or unique clinical practices. Across 108 randomized trials 
published between 1967 and 2013, Higa-McMillan et al. (2016) found that six treatments 
met the well-established criteria, including CBT (with parent involvement and Sertraline) 
and behavior therapy (exposure, modeling), and produced an average within-group post-
treatment effect size (ES) of 1.42. Eight treatments also were identified as probably 
efficacious, largely using CBT and/or family therapy approaches, with an average post-
treatment ES of 1.13. Two treatments were classified as possibly efficacious and again 
used CBT-based approaches but did not report the necessary data for ES estimation (i.e., 
means and standard deviations for anxiety outcome variables). In addition, six treatments 
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were classified as experimental including psychodynamic therapy, rational emotive 
therapy, and biofeedback training, while eight treatments were classified as questionable, 
including teacher psychotherapy, psychoeducation, and Eye Movement Desensitization 
and Reprocessing (EMDR). Post-treatment effect sizes for experimental treatments 
averaged 0.93 and questionable treatments averaged 0.50. This expansion of empirically 
supported treatments for pediatric anxiety, including six well-established and eight 
probably efficacious treatments, highlights significant progress made since the prior 
evidence-based update report published ten years ago by Silverman et al. (2008).  
Despite progress made in securing several efficacious treatments for pediatric 
anxiety, real-world access is strikingly low (each year, 60% to 80% of youth with anxiety 
and its related impairments never receive services; Beesdo, Knappe, & Pine, 2009; Kohn, 
Saxena, Levav, & Saraceno, 2003; National Academies of Sciences, Engineering, and 
Medicine, 2017). And, for youth who receive treatment services dropout rates are high 
and recovery rates, moderate. Specifically, youths attending an average of 25% of 
prescribed sessions (often 12 to 16 for typical pediatric anxiety protocols; Cummings et 
al., 2013; Weisz et al., 2017), while recovery rates of treatment completers tend to 
average 60% with remission falling by 10% over time (Barrett & Turner, 2004; Chavira 
et. al., 2004; Silverman et al., 2008). Given the substantial and significant problem of 
pediatric anxiety and identified limitations with treatment approaches, research efforts 
also have focused on advancing preventive interventions designed to interrupt the 
escalation of symptoms and the onset of anxiety disorders at the universal, selective, and 
indicated levels. Briefly, the Institute of Medicine classifies universal prevention as that 
which addresses the population at large; selective as that which targets those with an 
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elevated vulnerability; and indicated as that which focuses on those with disorder levels 
that are subsyndromal or high and projected to develop into diagnoses (O’Connell, Boat, 
& Warner, 2009). In the clinical child and adolescent area, the prevention of pediatric 
anxiety is as important as its treatment, particularly because prevention efforts appear to 
be promising in offering an additional avenue to maximize fit between the EBI, its 
possible delivery settings (e.g., schools, summer camps), and the needs of end-users (e.g., 
youth, caregivers, lay implementers) to reduce the burden posed by pediatric anxiety. In 
fact, several studies show that pediatric anxiety can be prevented via brief, non-
pharmacological, interventions; and like most treatments, preventive interventions draw 
on cognitive and behavioral therapy theory. Also, as it should be anticipated, preventive 
effects on clinical outcomes take time to emerge and are expected to vary by level (e.g., 
universal vs. indicated) (Fisak, Richard, & Mann, 2011); while positive preventive effects 
also are relatively stable. For example, at the universal level, small effects are often 
found, followed by greater effects on clinical outcomes at the selective and then at the 
indicated prevention level. And, relative to treatment, prevention efforts offer strong 
promise in reducing anxiety symptom levels or risk for anxiety disorder development 
(e.g., effect sizes tend to range from 0.17 to 0.22 for indicated prevention and from 0.35 
to 0.76 for treatment; Fisak et al., 2011; Reynolds et al., 2012; Weisz et al., 2017; 
Werner-Seidler et al., 2017). Moreover, given that preventive interventions are typically 
shorter in duration compared to treatments, delivered in non-clinical community settings 
(e.g., schools, after-school settings), and increasingly implemented by non-mental health 
professionals (teachers, behavior specialist), prevention offers another critical channel by 
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which EBIs could be disseminated and sustained at-scale for adequate public health 
impact. 
As such, this research sought to achieve two principal objectives. First, this study 
aimed at quantifying (via meta-analysis) the magnitude of effects produced by brief, non-
pharmacological interventions on pediatric anxiety outcomes. Within this aim, program 
effects were examined in the contexts of moderation, such that variations were expected 
as a function of two “families” of putative moderators relevant to intervention protocol 
(e.g., treatment versus prevention) and participant (e.g., youth age) characteristics. 
Second, this study aimed at evaluating the evidence-based status of brief, non-
pharmacological interventions, in an effort to draw conclusions that would inform clinical 
practice.  
In terms of hypotheses, relevant to the first aim, it was expected (and desired) that 
the interventions of focal interest herein would produce small to medium effect sizes on 
pediatric anxiety outcomes, which would be consistent with findings from meta-analyses 
of several brief non-pediatric anxiety interventions (e.g., Schleider & Weisz, 2017). Also 
expected (and desired) would be that larger effect sizes come from treatment, compared 
to prevention (indicated, selective, universal; Fisak et al. 2011; Reynolds et al., 2012). 
Clinically, one should desire large effects from treatment because this is the service often 
offered to youth that show the highest symptom levels and most severe impairment 
(empirically, higher risk levels tend to derive the earliest and greatest benefit from 
prevention; Spilt, Koot, & van Lier, 2013; Spoth, Trudeay, Redmond, & Shin, 2014; 
Verdurmen, Koning, Vollebergh, van den Eijnden, & Engels, 2014). In an exploratory 
way, other putative moderators (i.e., provider type, modality, theoretical approach, youth 
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age, ethnicity representation, gender) were considered and tested in terms of its relation 
to effect size. In the past, few studies have shown moderation effects. Reynolds et al. 
(2012) reported larger effect sizes by delivery modality with individually-delivered 
cognitive and behavioral therapy (CBT) for adolescents showing greater effects than 
group-based CBT, non-CBT, or non-specific child-focused services (albeit formal sub-
group analyses were not conducted to determine statistically significant variations). Fisak 
et al. (2011) reported larger effects for interventions delivered by mental health 
professionals compared to delivery by lay providers. This research did not uncover any 
other type of known moderator of response for interventions targeting pediatric anxiety. 
In terms of the second aim, it was anticipated that certain brief, non-pharmacological 
interventions could emerge as well-established or probably efficacious. For example, 
CBT (with and without parent involvement or medication), in vivo exposure, behavior 
therapy, and family therapy (e.g., CBT for child and parent) are already earmarked as 
well-established or probably efficacious in the treatment of pediatric anxiety. These 
levels of empirical support refer to typical protocols (Higa-McMillan et al., 2016); but 
since many reinvented EBIs (in both treatment and prevention) draw on the same 
efficacious components as typical protocols, some reinvented EBIs might already meet 
the well-established level (or at least probably efficacious), which would signal there is 
some level of readiness toward dissemination and implementation. 
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CHAPTER 2 
METHODS 
Study Search Procedure 
The principal source to select each study for evaluation was a computer index 
search using a combination of PsychINFO and Web of Science. Parameter selections 
were: categories (psychology, psychiatry), topics (intervention, treatment, psychotherapy, 
training, modification), evaluation (clinical, randomized, comparison, effect, outcome), 
and population (child, youth, adolescent). In conjunction with selected parameter options, 
searches were carried out using combinations of the following keywords: anxiety, 
generalized anxiety, separation anxiety, social phobia, social anxiety, specific phobia, 
therapy, prevention, fears, phobic, worry, and panic. Auto-explode options were used in 
all computer searches to ensure that all relevant topics within the broader categories were 
included. The computer index search was supplemented with manual searches of studies 
cited in published meta-analyses, reviews, references in targeted studies citing other 
RCTs, and “in press” or “first online” studies recommended by the two search engines.  
Study Selection 
Studies were included for consideration based on the following criteria: (1) 
participants were selected and included in the original study on the basis of measures that 
had some degree of evidence of psychometric reliability (e.g., published Cronbach alpha 
reliability coefficients) due to: (1a) clinical anxiety as evidenced by diagnoses and/or 
symptoms, (1b) subsyndromal anxiety symptoms indicative of increased risk for disorder 
development, (1c) the presence of known risk factors associated with anxiety disorder 
development (e.g., parent with a diagnosed anxiety disorder), or (1d) universal prevention 
  13 
efforts specifically targeting anxiety disorders; (2) the mean age of child participants was 
18 years or younger; (3) participants did not have a co-morbid neurodevelopmental 
disorder (e.g., autism spectrum disorder) or significant externalizing disorder; (4) random 
assignment to conditions used; (5) at least one condition evaluated a non-
pharmacological intervention with a maximum intervention “dosage” of 11 direct hours 
(including required booster sessions); and (6) condition protocols were clearly explained 
or specified. Studies of interventions involving medication only were excluded, as well as 
those focusing primarily on academic concerns, peer rejection or unpopularity, or 
“medical” problems (e.g., distress associated with a medical condition or procedure). 
Search efforts resulted 76 studies (including 26 published since Ost & Ollendick, 2017) 
meeting inclusion/exclusion criteria. Figure 1 shows the study search and study inclusion 
flowchart.  
 Study Coding Procedures 
 Studies were coded on variables relevant to quantitative characteristics used to 
calculate effect sizes. Anxiety outcome measures were included for effect size coding if 
the measure assessed anxiety symptoms, levels, or diagnoses using valid and reliable 
metrics (e.g., youth self-report, parent/caregiver report, behavioral observations, clinician 
assessments). For each eligible measure, the mean, standard deviation, and sample size 
was coded at each available assessment point.  
 Quantitative characteristics relevant to participant and intervention characteristics 
also were coded to evaluate effect size variations based on theory and published meta-
analyses (Reynolds et al., 2012; Weisz et al., 2017; Schleider & Weisz, 2017). The 
variables were: sex (female), race/ethnicity (minority representation), age (in years), 
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primary/targeted anxiety problem (specific phobia vs. mixed anxiety vs. another specific 
anxiety disorder), intervention level (treatment, targeted prevention, universal prevention) 
(the label name targeted is used to refer to selective and indicated prevention studies), 
focal intervention recipient or beneficiary (child, caregiver), primary delivery setting 
(research laboratory, community), provider (professional, non-professional or lay), 
training of providers (required vs. not required), supervision of providers (required vs. 
not required), intervention modality (individual, group, individual with digital supports, 
self-directed, digital only – e.g., attentional bias modification training), and comparator 
condition type (no-treatment or waitlist, placebo or attention control, another EBI). Two 
intervention design features relevant to dosage calculation also were coded: intervention 
length (the total time in weeks as defined by the intervention [e.g., 10 weeks]) and 
session duration, (average time per single session as defined by the intervention [e.g., 60 
minutes]). 
 Quantitative data from measures assessing constructs of interest were entered into 
a Microsoft Excel (Microsoft Corp., Richmond, WA) database with algorithms 
programmed to calculate effect sizes. To ensure reliability, Lipsey and Wilson’s (2001) 
recommendations were implemented. First, approximately three weeks following the 
original coding of the studies, 100% of the studies were re-coded in a separate database 
without access to the original coding file. Double-entered data were checked against the 
original database by an independent and trained rater. Data corresponding to sample and 
intervention variables were coded by two independent and trained raters and verified by 
the first author. Inter-rater reliability between the two coded databases was moderate to 
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high (0.86 > ICCs > 0.94) for continuous effect size and moderator data and substantial to 
almost perfect (0.79 > κappas ≥ 1.0) for categorical variables. 
Effect Size Calculation 
 To calculate between-group effect size estimates, the independent group pretest-
posttest (IGPP) procedure was used. The IGPP procedure allows for comparisons 
between two independent groups (e.g., intervention vs. control) on their corresponding 
mean change scores on some dependent measure using different standardized 
instruments. This increases confidence that observed differences are truly attributable to 
the intervention condition and not a result of nonspecific epiphenomenal factors (e.g., 
passage of time, attention; Hedges, 1982; Morris & DeShon, 2002). Between-group 
effect sizes were calculated for all anxiety outcomes from pre to post-intervention, as 
well as pre-intervention to follow-up using the following equation:  
𝐸𝑆#$%%& = ()𝑀+,-,			012 − 𝑀+452,			0126 − (𝑀+,-,			8412 − 𝑀+452,			8412)𝑆𝐷;44<-=,			;,- > ∗ @1 − 34𝑁 − 9F 
 In the first half of this equation, (𝑀+,-,			012 − 𝑀+452,			012)	is the mean difference 
for the intervention group, (𝑀+,-,			8412 − 𝑀+452,			8412) is the mean difference for the 
control group, and 𝑆𝐷;44<-=,			;,- is defined as: 
𝑆𝐷;44<-=,			;,- = (𝑛HI − 1)𝑠HIK + (𝑛HK − 1)𝑠HKK(𝑛HI − 1) + (𝑛HK − 1)  
 Here, 𝑛HI is the number of subjects in the intervention group, 𝑛HK is the number 
of subjects in the control group, 𝑠HI is the pre-intervention standard deviation for the 
intervention group, and 𝑠HK is the pre-intervention standard deviation for the control 
group. Pre-intervention standard deviations were used as they were measured before any 
  16 
intervention has happened and are thus more likely to be consistent across studies 
(Becker, 1988).  
 As noted by the second half of the IGPP equation, effect sizes were adjusted to 
yield Hedge’s g estimates, which is recommended to account for the potential upward 
bias of Cohen’s d effect sizes when based upon a collection of studies that include small 
sample sizes (e.g., N < 20; Lipsey & Wilson, 2001). Effect sizes also were weighted by 
the reciprocal of the standard error to account for differences among sample size and 
variances using the following equation (Lipsey & Wilson, 2001): 
𝑤5N = 	 1OP𝑛HI + 𝑛HK𝑛HI𝑛HK + (𝐸𝑆#$%%&)K2(𝑛HI + 𝑛HK)RK
 
 Finally, to calculate within-group effect sizes, the difference between pre and 
post-intervention (and follow-up) means was divided by the pre-intervention standard 
deviation, then adjusted for sample size bias using the Hedge’s g correction. For both 
between- and within-group effect sizes reported herein, positive values reflect effects that 
are occurring in the expected direction (i.e., the intervention is related to the theorized 
clinical improvements) whereas a negative effect size value reflects continued clinical 
deterioration (i.e., the intervention is not related to the theorized clinical improvements). 
A 95% confidence interval was derived for each effect size aggregate and labeled using 
the standards suggested by Cohen (1988): small (0.20 or less), medium (about 0.50), and 
large (0.80 or over). 
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Meta-Analytic Procedure  
 Individual studies frequently reported multiple measures of anxiety outcomes. 
The inclusion of multiple measures per singular construct violates assumptions of 
independence that underlie meta-analysis (Rosenthal & DiMatteo, 2001). When this 
assumption is violated, sample sizes are inflated and standard error estimates are 
distorted, producing biased effect size estimates. To maintain assumptions of 
independence, and per the recommendation of Lipsey and Wilson (2001), multiple effect 
sizes for a single construct within studies were averaged prior to synthesis with effect 
sizes from other studies to ensure that each study only contributed a single effect size 
estimate.  
 In terms of statistical approach, random effects models were used to calculate 
overall weighted effect sizes. Unlike a fixed effect approach that assumes between-study 
differences are due to sampling error alone, random effects models assume that between-
study differences are the result of both sampling error and other sources of variability 
(e.g., putative moderators, study design, random differences). In this way, random effects 
models enable broader generalizability of meta-analytic findings to populations beyond 
those under investigation (Cooper et al., 2009; Hedges, 1983; Rosenthal & DiMatteo, 
2001). To confirm the a priori decision to use random effect model approach, and given 
the considerable methodological differences across studies, heterogeneity of effect sizes 
was determined using the Q-test. 
𝑄 =T𝑊V𝑌V −	(∑ 𝑊V𝑌V)YVZI K∑ 𝑊VYVZIYVZI  
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 The Q-test examines whether between-study variation could be completely 
explained by within-study sampling error or whether the variation among effect size 
values reflect real and important differences between studies. A significant Q-test value 
indicates there is significant variability in effect sizes beyond sampling error that should 
be examined via formal meta-moderation analyses. When the Q-test was significant, the 
I2 statistic also was calculated:  
𝐼K = 	𝑄 − (𝑛 − 1)𝑄  
 The I2 statistic provides an estimate of the proportion of observed variance that 
reflects true differences among effect sizes, with guidelines suggesting that 25%, 50%, 
and 75% values represent low, moderate, and high levels of heterogeneity, respectively 
(Carpenter et al., 2018; Higgins, Thompson, Deeks, & Altman, 2003).  
Validity Assessment 
 A byproduct of peer-reviewed publication standards and procedures is the “file-
drawer problem,” which suggests that published studies are more likely to report 
statistically significant results than unpublished studies (Rosenthal, 1991). As such, meta-
analytic reviews may yield a systematic upward bias due to the omission of null findings 
such that effect sizes may not accurately represent the ‘truth’. To address the file-drawer 
problem and potential publication bias, the fail-safe N (Rosenthal, 1991) was calculated 
using the following equation: 
𝑘] = 𝐾	(𝐾_` K − 2.706)2.706  
 In this equation, K is the total number of studies assessing outcome or mediator 
variables in the meta-analysis and Z is mean effect size produced by the K studies. The 
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FSN represents the number of studies with a mean effect size of zero that would be 
needed to reduce an effect size to non-significance. Thus, the FSN approximates how 
resistant calculated effect sizes are to null effects. 
Moderators of between-group effect sizes 
 To ascertain the potential moderators of between-group effect sizes, a series of 
analog to ANOVA tests were conducted using the International Business Machines’ 
Statistical Package for the Social Sciences (IBM’s SPSS) with the MetaF macros 
provided by Wilson (2003). This macro uses a mixed effect model to test for moderation, 
whereby studies within subgroups are pooled using random effects approaches, while 
tests of significance between subgroups are conducted using fixed effect approaches 
(Borenstein et al., 2009; Spinhoven et al., 2018). In addition, two approaches were taken 
to increase confidence in moderator findings. First, analyses were only conducted if the 
moderator category contained at least three studies per sub-group because meta-analytic 
moderation estimates have shown to be poor when the number of studies is very small 
(Weisz et al., 2017). Second, to maximize meta-analytic power in detecting significant 
moderation effects, separate analyses were conducted for each candidate moderator 
variable at each focal time point (i.e., pre- to post, pre to follow-up) (Raudenbush & 
Bryk, 2002; Van den Noortgate et al., 2013). To control for the increased possibility of 
Type I error due to the number of separate moderator analyses, a Holms-Bonferroni 
correction was applied. The Holms-Bonferroni adjusts p-values based on the total number 
of contrasts within a moderator family as to maintain experiment-wise error rates at a 
target alpha level while yielding more statistical power than a traditional Bonferroni 
correction. Briefly, and focusing on one moderator family at a time (intervention, 
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participant), analog-to-ANOVA tests were used (or meta-regression for continuous 
variables) to test for moderation. Then, the contrast with the smallest p-value was 
evaluated against an alpha of 0.05 divided by the total number of contrasts in the 
moderator family. If the contrast remained statistically significant, then the contrast with 
the next smallest p-value was tested using an alpha level of 0.05 divided by the number 
of remaining contrasts in the moderator family. This process continued until a 
nonsignificant difference within the family was observed; at which point, all remaining 
contrasts in the family were considered nonsignificant (for a more detailed discussion of 
the Holms-Bonferroni correction, see Jaccard and Guilamo-Ramos, 2002). 
Dosage Calculation  
For this research ‘dosage’ was calculated by multiplying intervention length by 
the product of session duration and session frequency. Session frequency was obtained by 
dividing total number of intervention sessions by intervention length. In addition, the 
average number of days in-between sessions was calculated by multiplying the inverse of 
intervention session frequency by seven (representing number of days in a week). From a 
dosage perspective, in-between session time could be considered an estimate of single 
dose duration or the time in which a single intervention dose (i.e., individual session) has 
the potential to have effects on targeted outcomes (via home practice assignments, for 
example). This approach to intervention dosage calculation is based on Berkel et al. 
(2011), Gierisch et al. (2010), and Glasgow et al. (2014). 
Evidence Base Status Evaluation 
 Evaluation criteria adopted by the Society of Clinical Child and Adolescent 
Psychology (SCCAP; Southam-Gerow & Prinstein, 2014) from the guidelines originally 
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articulated by Chambless and colleagues (Chambless et al., 1996, 1998; Chambless & 
Hollon, 1998) were used to determine the evidence-based status of brief, non-
pharmacological, interventions for pediatric anxiety. Criteria are shown in Table 1. Using 
the M.1 to M.5 criteria listed in the table, two independent and trained evaluators rated 
the methodological robustness of each study, with coding verified by the first author. 
Initial agreement between evaluators was 98% with raters differing in their coding of the 
M.5 criterion for one study. The raters and first author discussed each discrepancy and 
then a 100% agreement between parties was reached.  
 Upon establishing the methodological robustness of each study, ‘intervention 
families’ were created to facilitate evidence-based status classification. Interventions 
were aggregated into distinct when they shared most therapeutic elements with 
comparable theoretical foundations and prescribed the same intervention dosage. When 
interventions had principally different theoretical underpinnings, they were separated into 
distinct intervention families. Distinct families also were created when interventions 
shared comparable theoretical foundations but prescribed different intervention dosage 
amounts. This approach was taken as to facilitate increased precision in identifying 
minimal intervention dosage thresholds necessary for clinically significant change in 
anxiety outcomes. Intervention families were then classified based on their empirical 
support into one of five “levels”, including: well-established, probably efficacious, 
possibly efficacious, experimental, and questionable. Descriptions of each level, 
including evidentiary requirements, are presented in Table 1.  
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CHAPTER 3 
RESULTS 
Characteristics of Included Studies 
The final sample of studies consisted of 76 RCTs, including 40 that were 
prevention focused (13 indicated, 4 selective, and 17 universal) and 36 treatment studies. 
The total sample size was 17,203 youth between the ages of 3 to 18 years (M = 10.61, SD 
= 2.75) with 55% being female. Twenty-five studies evaluated interventions with samples 
consisting mostly of Caucasian youth, while only three studies evaluated interventions 
with majority non-Caucasian samples (Ginsburg & Drake, 2002; Kato & Shumizu, 2017; 
Pina et al., in press). The remaining 48 studies did not report sample demographic 
information to ascertain ethnic minority representation. In terms of intervention 
characteristics, 114 independent intervention conditions were evaluated, with an overall 
average dosage of 6 direct hours (range = 1 to 10; SD = 2.64), delivered in about 8 
sessions (range = 1 to 12; SD = 2.90), across 7.14 weeks (range = 1 to 16; SD = 3.47), 
with an average of 6 days between intervention sessions (range = 0 to 14; SD = 2.14). 
Approximately, 80% (n = 60) of interventions targeted pediatric anxiety broadly, without 
a focus on a particular disorder; of the remaining interventions, 13% (n = 10) targeted 
specific phobias and 8% (n = 6) focused on social anxiety. Most interventions were based 
on cognitive and/or behavioral therapy theory (63%), delivered by highly trained mental 
health professionals (67%), and largely focused on youth as the primary intervention 
recipient (91%). In terms of intervention modality, 48.5% (n = 32) of studies reported on 
protocols delivered in group format, 21.2% (n = 14) individual format, 21.2% (n =14) 
used some form of technology in program delivery (e.g., internet, CD-ROMs, computer 
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games). About 14% (n = 9) of studies used attention-bias modification training (ABMt) 
protocols and 4.5% (n = 3) were bibliotherapy. With regard to comparator conditions, 
53% (n = 41) of studies used a waitlist or no treatment control, 22% (n = 17) compared 
an intervention to an active control condition (e.g., attention control, education support), 
and 8% (n = 6) used another EBI as the comparator.  
Included studies are summarized in Table 2. Column 1 names the investigatory 
team and publication date. Column 2 reports participants’ characteristics (i.e., age, sex, 
clinical inclusion criteria) and randomization to condition and comparator. Column 3 
describes significant program effects and condition comparison results. Finally, column 4 
specifies Table 1 criteria relevant to the methodological robustness for each study. A total 
of 64 studies were considered methodological robust in that they met M.1 to M.5 criteria. 
Twelve studies did not meet M.5 criterion because the sample size per 
condition/comparator was too small to detect reliable effects (i.e., Attwood et al., 2012; 
Barrett et al., 2001; Dewis et al., 2001; Gallagher et al., 2004; Ginsburg & Drake, 2002; 
Hains, 1992; Muris et al., 1998; Muris et al., 2002; Sheslow et al., 1982; Stallard et al., 
2011; Tillfors et al., 2011; Whiteside et al., 2015).  
Effect Sizes Produced by Brief, Non-Pharmacological Interventions 
Of the total sample of 76 studies, 64 reported data necessary to calculate between-
group effect sizes (i.e., raw means and standard deviations for outcomes measured at a 
minimum of two time points for an intervention and comparator). Calculated effect sizes 
are reported in Table 4. In the table, column 1 corresponds to the level of intervention. 
Column 2 shows the number of studies that contributed to the effect size calculation, and 
column 3 indicates the meta-analytic sample size. Column’s 4 through 7 report the 
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weighted Hedge’s g effect sizes of anxiety outcomes and corresponding effect size 
standard deviations, 95% confidence intervals, and fail-safe N. Finally, column 8 reports 
Q-test statistics relevant to heterogeneity among effect sizes.  
Findings showed that brief treatments produced a pre to post effect size of 0.35 
(SDg = 0.36) whereas brief prevention produced a pre to post effect size of 0.13 (SDg = 
0.24). Within brief prevention, there was some variability. Indicated and selective 
prevention produced effect sizes of 0.22 (SDg = 0.24) and 0.31 (SDg = 0.25). Universal 
prevention produced an effect size of 0.09 (SDg = 0.19); from pre to post. Overall, fail-
safe N calculations were generally robust; however, the fail-safe N for selective 
prevention was low (FSN = 2) suggesting that selective prevention effects would likely 
be altered by the presence of studies producing null effects. The fail-safe N for selective 
prevention could be related to the small number of included studies (n = 4).  
Results for pre to follow-up effect sizes were based on the 30 studies that reported 
follow-up data with continuation assessments ranging from 1 month to 4 years post-
intervention. The meta-regression showed that follow-up duration did not account for 
significant differences in effect sizes (Q = 2.19 [1, 116], p = .14); accordingly, effects 
were averaged across assessments such that each study in the meta-analysis contributed a 
single estimate of pre to follow-up effects (M = 8.88 months; SD = 8.76). As shown in 
Table 4, the effect size for brief anxiety treatments decreased slightly (approximately 
0.05 g-units) from pre-intervention to follow-up suggesting that these interventions are 
mostly maintaining effects overtime rather than showing growth in clinical outcome 
gains. In contrast, prevention produced an overall effect size from pre-intervention to 
follow-up of 0.22 (SD = 0.23) representing an increase of 0.09 g-units from pre to post-
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intervention effects. This suggests some growth in clinical outcome gains over time. It is 
important to highlight that the 0.09 g-unit increase appears to be largely driven indicated 
and universal prevention trials, not selective prevention efforts. Indicated prevention 
produced a pre to follow-up effect size of 0.30 (SD = 0.29), universal prevention 
produced a pre to follow-up effect size of 0.17 (SD = 0.17), and lastly, selective 
prevention produced a pre to follow-up effect size of 0.21 (SD = 0.10). 
Moderators of Effect Sizes Derived by Brief, Non-Pharmacological Intervention 
There was moderate to high degree of heterogeneity and thus moderation analyses 
were conducted as planned. That is, heterogeneity statistics indicated a significant degree 
of between-study variance in effect sizes from pre to post (Qw = 189.60 [63], p < .001) 
and pre to follow-up (Qw = 91.94 [29], p < .001). I2 statistics indicated that 46.80% to 
70.30% was true between-study variation; pre to follow-up effect sizes had I2 rates of 
68.40% to 73.77%. Tables 5 and 6 present findings for all analog-to-ANOVA moderation 
tests using pre to post intervention and pre to follow-up effects sizes. 
From pre to post-intervention, only level of intervention emerged as a significant 
moderator of effect sizes (Qb = 28.11, p < .001), such that treatment yielded larger effect 
sizes (g = 0.26; 95% CI 0.16 to 0.37) than targeted prevention (g = 0.21; 95% CI 0.12 to 
0.30). Universal prevention (g = 0.09; 95% CI -0.05 to 0.23) effects were non-significant. 
In terms of the levels of intervention tested as targeted prevention, analyses revealed no 
significant differences in pre to post effect sizes between indicated and selective 
prevention (Qb = 0.32, p < .57). However, there was a significant difference in pre to post 
effect sizes between targeted and universal prevention (Qb = 3.84, p < .05). None of the 
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participant and no other intervention level characteristic emerged as significant 
moderators of pre to post or pre to follow-up effect sizes. 
Evidence-Based Status of Brief, Non-Pharmacological Interventions for Pediatric 
Anxiety 
As shown in Table 3, in vivo exposure treatment (in one/single session with 3 
intervention hours) for specific phobias met the well-established criteria. Five brief 
interventions met the probably efficacious criteria: CBT (9 to 10 hours), clinician 
supported digital parent training (6 hours), behavioral therapy (8 hours), and exposure-
based CBT with social skills training (3 hours). Seventeen interventions were classified 
as possibly efficacious: CBT with or without parents (8 hours), clinician supported digital 
CBT (3 to 7 hours), and clinician supported bibliotherapy (3 to 5 hours). Also, possibly 
efficacious was ABMt: training away from threatening stimuli (1,920 trials across 4 
sessions) and training toward positive stimuli (640 trials across 4 sessions). There is a 
handful of additional brief interventions meeting the possibly efficacious criteria (include 
stress inoculation training; growth mindset training, psychoeducation in-vivo exposures 
in 1.5 hours, and emotive imagery for specific phobias). Eleven interventions were 
classified as experimental. Neurofeedback with exposure and attention training (5 hours), 
as well as biofeedback interventions with relaxation training (6 hours) as delivered via 
immersive computer video games were classified as experimental because they produced 
significant within-group reductions in pediatric anxiety outcomes, but no between-group 
comparisons against active controls. Eye movement desensitization and reprocessing 
(EMDR) (2.5 hours) was found to be questionable because it was not better (or 
equivalent) when compared to in-vivo exposures. 
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Minimal Interventions Needed for Change in Pediatric Anxiety Outcome 
Between-group, pre to post-intervention effect sizes were calculated for well-
established and probably efficacious brief interventions along with the corresponding 
dosage scores (from number of sessions, length of session, frequency of sessions). Figure 
2 illustrates the data. On the y-axis the between-group, pre to post-intervention effect 
sizes, are plotted. On the x-axis, level of intervention (treatment, targeted prevention, 
universal prevention) is plotted. The figure also references published meta-analysis effect 
size data from typical length interventions for pediatric anxiety.  
In terms of treatment, as shown in the figure, approximately 3 hours of 
intervention for a specific phobia is able to produce a mean effect size of 0.36 (SD = 
0.43; 95% CI = 0.08 to 0.80; k = 5) when in-vivo exposures are implemented. In addition, 
about 7 hours of CBT for pediatric anxiety disorders is able to produce a mean effect size 
of 0.50 (SD = 0.52; 95% CI = 0.02 to 0.97; k = 6). As shown in the figure, these effect 
sizes are below the average effect that can be obtained from a typical length EBI, but the 
upper confidence levels for these brief treatments fall within the confidence level range 
reported in the literature for typical length EBI (per Reynolds et al. 2012 meta-analysis). 
Focusing on this overlap, it might be the case that some youth could benefit from a brief 
EBI as much as youth who receive the typical length treatment for pediatric phobias and 
anxiety. With regard to pre to follow-up (about 5 months), the mean effect size for CBT 
was 0.33 (SD = 0.47; 95% CI = 0.04 to 0.71; k = 3). There was an insufficient amount of 
data (i.e., more than one study) to calculate pre to follow-up effect sizes for the other 
treatments (parent training, behavior therapy, in vivo exposures).  
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Turning to prevention, targeted (indicated and selective) efforts are able to 
produce to produce a mean effect size of 0.41 (SD = 0.30; 95% CI = 0.13 to 0.69; k = 6) 
from about 8 hours of cognitive and behavioral intervention. Interestingly, these 8 hours 
of EBI services are producing almost twice the effect size as typical length protocols (per 
Fisak et al., 2011 meta-analysis). In contrast, the effect size for universal prevention was 
small (0.09, SD = 0.15; 95% CI = 0.01 to 0.18; k = 12) and less than the corresponding 
universal prevention effect from typical length protocols. The pre to follow-up (about 9 
month) effect size for targeted prevention was 0.45 (SD = 0.36; 95% CI = 0.08 to 0.82; k 
= 5) and for universal it was 0.20 (SD = 0.17; 95% CI = 0.04 to 0.35; k = 7; an increase of 
0.08 g-units from pre to post-intervention). 
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CHAPTER 4 
DISCUSSION 
In the clinical child and adolescent psychology area, significant strides have been 
made to situate EBIs in community practice settings (Powell et al., 2015; Lyon & 
Koerner, 2016). Our research augments the knowledge-based by showing that a new-
wave of brief, non-pharmacological, interventions for pediatric anxiety might reach 
community practice settings. Some brief interventions for pediatric anxiety are now well-
established or probably efficacious and demonstrate significant clinical changes, indexed 
by effect sizes resulting from our meta-analysis. Thus, the hypothesis that brief 
interventions produce small to medium effect sizes on pediatric anxiety outcomes was 
confirmed for one well-established intervention: in-vivo exposures for the treatment of 
specific phobias and four probably efficacious interventions: child focused exposure-
based CBT with social skills training for indicated preventions and early intervention, 
CBT (no social skills training), behavior therapy, and parent focused training  
Ollendick and King (1998) and Higa-McMillan et al. (2016) indicated that in-vivo 
exposures for specific phobias is an empirically supported treatment but data now show 
that significant positive change can be achieved in as little as one session (~3 hours; Ost 
et al., 2001; Ollendick et al., 2009). Silverman, Pina, and Viswesvaren (2008) and Higa-
McMillan et al. reported that CBT for anxiety disorders is an empirically supported 
treatment but data now show that significant positive change can be achieved in as few as 
six sessions for indicated prevention and early intervention (~3 hours), and in as few as 
eight parent training sessions for anxiety treatment (~6 hours, delivered digitally with 
clinician support) (Donovan & March, 2014; Morgan et al., 2017). Similar to past 
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research, we found larger effect sizes (ES) for treatment compared to prevention 
(indicated, selective, universal; Fisak et al. 2011; Reynolds et al., 2012) but results 
suggested that streamlining pediatric anxiety treatments into briefer formats might lead to 
declines in clinical effectiveness (e.g., ES: ~0.70 for typical length treatments; Reynolds 
et al., 2012; compared to 0.35 for brief-treatments). Such declines appear to be less 
apparent when it comes to prevention (ES: 0.17, Fisak et al., 2011; 0.13 for brief-
prevention); however, our findings from prevention require replication with additional 
studies because the fail-safe N estimates were low, and most protocols were universal or 
indicated. 
At this juncture, the evidence suggests there are minimal interventions for clinical 
change: in-vivo exposures for specific phobias (~3 hours, one session), CBT with social 
skills training (~3 hours, six sessions for indicated prevention and early intervention, and 
parent training (~6 hours, eight digital modules with clinician support) (Donovan & 
March, 2014; Morgan et al., 2017; Pina et al., in press; Ost et al., 2001; Ollendick et al., 
2009; Weersing et al., 2017). Importantly, brief interventions appear robust in the context 
of moderation. Only brief treatments produced larger effects than brief-prevention, which 
is desirable because diagnosed youth often show the largest breach between normal and 
clinical anxiety. No other candidate mediator variable was statistically significant. The 
null-moderation findings might be explained by low statistical power (only 44 studies or 
58% reported data to afford moderation) and study design restrictions (little variability 
from data corresponding to controlled efficacy trials). 
Moving forward, efforts should focus on facilitating the uptake of brief 
interventions in community practice settings. A major concern that needs to be addressed 
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is the gap between the architecture of brief-intervention and insurance system coverage. 
For instance, some brief interventions are designed to be intensive (e.g., one session 
lasting several hours) but providers only can submit service claims corresponding to one-
hour session per day. Another way to help facilitate uptake is to determine if brief-
interventions are cost-effective and thus attractive to insurance companies or other 
organizations paying for the services. Clinically, facilitating the uptake of brief 
interventions in community practice settings might translate into informing providers 
about which intervention components could be augmented in dosage to achieve stronger 
clinical outcomes. Unfortunately, dosage augmentation is often linked to knowledge of 
mediators, which is scant. No study relevant to a well-established or probably efficacious 
brief-intervention has tested mediation using an analytic approach that involves temporal 
order (a requirement for inferring causality; Kraemer et al., 2002; Carper, Makover, 
Kendall, 2018). There are some data pointing to factors that might have potential 
mediation effects and thus could serve as targets for dosage augmentation. For instance, 
in Pella et al. (2016), changes in parental modeling of anxiety (at post and 6-month 
follow-up) emerged as a significant mediator between 8-sessions of family-based CBT 
and child anxiety severity at 1-year follow-up. In another study, Liu et al. (2018) found 
that changes in threat processing (indexed as ventrolateral prefrontal cortex (vlPFC) 
activation) mediated the relation between a single-session intervention (attention bias 
modification training in 320 digital trials - away from threat) and anxiety symptoms at 
immediate post-intervention. In Ollendick et al. (2017), changes in harm beliefs and 
coping efficacy emerged as significant mediators between one session (3 hours) of in-
vivo exposures for specific phobia and changes in clinician severity ratings of anxiety 
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symptoms from pre to post and pre to 6-month follow-up. In addition, modifying anxious 
cognitions and improving coping self-efficacy could be targets for dosage augmentation 
as these two factors have emerged as likely mediators of typical length CBT interventions 
for pediatric anxiety based on findings from several RCTs (Treadwell & Kendall, 1996; 
Kendall & Treadwell, 2007; Lau et al., 2010; Pereira et al., 2018; Kendall et al., 2016; 
Maric et al., 2013; Essau et al., 2012; Spence et al., 2017); however, this would need to 
be established via additional research efforts.  
Limitations and Future Directions 
While the present dissertation advances knowledge regarding the viability and 
evidence-based status of brief, reinvented EBIs for pediatric anxiety, several limitations 
are important to consider when interpreting findings. First, as with all reviews, findings 
are limited to the studies included in the analyses. The inclusion criteria of the present 
research focused on identifying (and evaluating) published RCTs that met 
methodological indicators of robustness articulated by Southam-Gerow and Prinstein 
(2014) (e.g., utilization of treatment manuals, clearly delineated target population). This 
is particularly relevant when considering the current evidence-base of digital health 
interventions, an important avenue that will likely play an integral role in addressing 
need-to-access gaps in mental health services, have largely relied on non-randomized 
designs (e.g., open trials, time-series, match-control designs). Second, most studies 
included in the present research (86%) evaluated interventions under controlled, efficacy-
focused conditions versus real-world, effectiveness conditions. This is important because 
intervention-related effect sizes often decrease when EBIs are transported into real-world 
conditions (Fixsen et al., 2018). Third, the evaluation and classification of identified 
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brief, non-pharmacological interventions focused on anxiety outcome measures without a 
systematic examination of the efficacy of the protocols in terms of performance in 
improving program targets (e.g., cognitions) or comorbid symptoms or disorders (e.g., 
depression). While this approach enabled a greater degree of generalizability, the trade-
off was less specificity of findings beyond anxiety outcome variables. Thus, a key avenue 
of future investigation is a deeper examination of these more specific and granular 
outcomes. Fourth, effect sizes were based on an aggregate of anxiety outcome measures 
that met a minimum criterion of psychometric strength (i.e., at least one documented 
psychometric property [e.g., reliability coefficients]). However, measurement error 
attenuates study-level effect sizes and can lead to incorrect conclusions regarding the 
presence of moderating variables and magnitude of summary effect sizes. Correcting for 
measurement error is crucial for obtaining a true picture of the stability of effect sizes 
across studies (Schmidt & Hunter, 2014). Thus, because of this lack of reporting, the 
impact of variability in measurement reliabilities on summary effect sizes is unknown. 
Fifth, this research did not examine, in depth, whether intervention effects varied by 
anxiety disorder type (e.g., GAD, SoP, SAD) because more than 60% of studies focused 
on youth with mixed or heterogenous anxiety problems. However, anxiety disorders are 
highly comorbid with themselves such that youth diagnosed with one disorder are more 
likely to experience other anxiety disorders (Higa-McMillan et al., 2016). More 
specifically, homotypic comorbidity rates between anxiety disorders in youth populations 
range from 33% to 67% (Bennett et al., 2013). Nevertheless, considering the role of co-
morbid anxiety disorders within intervention efforts is likely to be important as to 
facilitate the personalization of interventions to meet individual needs. Finally, while pre 
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to follow-up effect sizes were able to be calculated, these should be considered, with 30 
studies including at least one follow-up assessment, most (75%) were 12 months or less. 
Thus, the long-term impact and durability of intervention effects (> 12 months) of these 
briefer protocols represents an important future research direction.  
Research Recommendations 
Moving forward, we must address important questions so that brief evidence-
based psychosocial interventions can be adopted and sustained in real-word settings. 
Based on the findings from the present dissertation, below are several factors that the 
next generation of intervention research should consider when developing, evaluating, 
and disseminating brief, and reinvented treatment and prevention programs for pediatric 
anxiety. 
1. Increased systematic evaluation of reinvented EBIs, including in the context of 
typical protocols. Effect sizes derived from brief EBIs for pediatric anxiety are 
smaller than those reported in published meta-analyses evaluating protocols of 
typical length (but are largely within effect size ranges).  Although briefer 
protocols are producing smaller effect sizes, they may be more efficient in 
producing significant improvements in anxiety symptoms and diagnostic recovery 
based on dosage. For example, the dosage for typical length treatments often 
ranges from 12 to 16 hours compared to versus brief treatments that range from 3 
to 10 hours. By reducing the amount of time to implement, for instance, the 
greater the service capacity available in community settings, as providers would 
be able to serve more youth and families in shorter amount of times. In addition to 
exploring this possibility, future research also should evaluate reinvented against 
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typical length efforts to gain a more precise understanding as to the difference or 
equivalence of program effects (e.g., using non-inferiority randomized designs). 
This also includes longer-term follow-up assessments (> 12 months) in order to 
gain a better sense as to the durability of effects obtained by brief, reinvented 
efforts.  
2. Move beyond efficacy testing with increased attention towards external validity, 
real-world implementation, and use of novel designs. An important step in 
supporting the adoption and sustainment of evidence-based psychosocial 
interventions in real-world settings is to start moving beyond efficacy studies. 
Efficacy trials adhere to generally stringent inclusion/exclusion criteria and tend 
to rely on interventionists (e.g., graduate students, clinical psychologists) serving 
under high levels of fidelity to manuals and emphasize internal validity. In this 
way, efficacy evaluations embody significant barriers in the provision and access 
of evidence-based care in community settings and observed effects may be 
representative of what might be obtained under real-world conditions. At this 
point, this research advocates for focused efforts to move intervention research 
serving anxious youth and their families into effectiveness settings and to 
implement novel treatment designs (e.g., hybrid trials; Curran et al., 2012) to 
ascertain real-world effects of reinvented EBIs.  Effectiveness trials and hybrid 
designs emphasize external validity (few inclusion and exclusion criteria), lessen 
geographical and transportation restrictions in the provision of care (Yancey, 
Glenn, Bell-Lewis, & Ford, 2012), and capitalize on the typical infrastructures of 
the community, such as primary care, schools, neighborhood clinics, emergency 
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rooms, and child welfare (Chavira et al., 2014; Asarnow et al., 2005). In 
effectiveness settings, providers generally have diverse experiences and expertise 
(guidance counselors, behavior specialists, social workers, parent liaisons, 
promotores/as) and have experience working with different types of youth and 
families (Durlak, 2015; Grumbach & Mendoza, 2008). Moreover, real-world 
evaluations of reinvented EBIs with minimal inclusion/exclusion criteria might 
enable more diverse and heterogeneous samples of youths and families to inform 
potential adaptations. For example, in the present research, only three trials 
reported included a significant degree of ethnic minority representation and none 
tested moderation by ethnicity/race. Moreover, similar to concerns outlined by 
Polo et al. (2018) and Pina et al. (2019), Asian American and Native American 
youth are still largely absent from the treatment outcome literature in general, and 
almost non-existent in brief EBIs for anxiety. For these reasons, effectiveness 
research offers rich opportunities for advancing intervention science for anxious 
and phobic youth, while providing opportunities for increased understanding as to 
how these protocols could be made more robust and amenable to the unique needs 
of youth and families. 
3. Examine dose-response relations. The present research represents an important 
step towards identifying minimal dosage thresholds for well-established and 
probably efficacious interventions. However, dosage recommendations reported 
herein represent mean estimates that do not take into account individual dosage 
needs. As such, future research should systematically evaluate relations between 
intervention dosage and youth responsiveness as demonstrated by gains in clinical 
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outcomes. Knowledge derived from these efforts could provide more specific 
insight relevant to dosage levels that are optimal for change. Understanding 
dosage thresholds, for example, could enable the use of dynamical and adaptive 
interventions that are responsive to individual needs, strengths, and contexts. In 
this way, deeper examinations of intervention dose-response effects could identify 
ways in which protocols could be adapted to align with personalized medicine 
initiatives (Riley et al., 2014).  
4. Increase understanding of how reinvented, brief EBIs for pediatric anxiety are 
achieving effects (i.e., mediators). Knowledge of intervention-related mechanisms 
of change is important as it may help improve the precision of established 
interventions, guide new intervention models, enhance measurement tools, refine 
psychosocial change theories, and inform practice efforts in the absence of 
validated intervention packages (Holly, Stoll, Rapp, Pina, & Chavira, 2018). 
Illustratively, interventions could become more precise in affecting planned 
outcomes by amplifying the critical components or mediators, while minimizing 
or removing unsuccessful components. In this way, mediator-driven interventions 
could help augment short- and long-term program effectiveness, while yielding 
streamlined interventions that are more amenable for large-scale, sustainable 
dissemination in real-world practice settings. Out of the 76 studies included in the 
present research, just six conducted formal mediation analyses. Of those, only one 
reported significant finding from a test of mediation that used a robust analytic 
approach that accounted for temporal order (Pella et al., 2016), a critical 
requirement for classifying a mediator as a causal mechanism between 
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interventions and planned outcomes (Kraemer et al., 2002; Carper, Makover, 
Kendall, 2018). The remaining studies that evaluated mediation utilized 
concurrent or cross-sectional mediation design, where the mediator variable was 
assessed concurrently with the outcome variable and precludes the possibility of 
elucidating the precise sequence of changes that might establish temporal 
precedence. The limited scope of mediation, however, is not due to a lack of 
available data. Specifically, most interventions in the present research included 
clinical content linked to two significant mediators of typical length protocols for 
pediatric anxiety (changing anxious cognitions and improving coping self-
efficacy). And, 50% (n = 38) of studies assessed change in at least one candidate 
mediator variable. Collectively, this represents a considerable number of missed 
opportunities to evaluate mediation effects of brief interventions for pediatric 
anxiety. Thus, future RCTs should more frequently measure theory-driven 
mediators, be responsive to timing of change in mediators in relation to 
assessment (as guided by theoretical model), and test mediation using robust 
analytic strategies such as the product of coefficients method using bias-corrected 
bootstrapped and asymmetric confidence interval (see MacKinnon, 2008; Toglifi 
& MacKinnon, 2011). Better measurement and analysis of the supposed 
mediators underlying changes in intervention outcomes would assist in 
identifying successful and unsuccessful portions of treatment and prevention 
efforts (MacKinnon et al., 2013). This information could help determine which 
intervention components and targets are crucial for changes in planned outcomes, 
allowing reinvented EBIs to be made more precise and streamlined.  
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5. Improve readiness of interventions for real-world implementation. Despite the 
EBIs evaluated in the present research being briefer in terms of planned dosage 
(as compared to typical length protocols), other structural characteristics need to 
be systematically examined to gain insight into other design features of brief EBIs 
that need to be reinvented to be more usable, scalable, and sustainable. For 
example, briefer EBIs likely have greater potential for reaching individuals not 
currently served or those not being well served (with evidence-based practices) 
and scalability by function of their brevity. However, because most of the 
identified EBIs have evaluated under highly controlled efficacy conditions, other 
design features need to be examined and likely reinvented to be positioned to 
reach public health impact. For example, 66% of the interventions evaluated in 
the present research were delivered by highly trained service providers (e.g., 
doctoral students, psychologists, counselors) with extensive pre-service training 
(10 or more hours) and on-going supervision or clinical consultation (usually on a 
weekly basis for 60 to 90 minutes). While training and supervision or consultation 
efforts are important in ensuring, as best as possible, high quality and fidelity of 
implementation, most current variants also are resource-intensive (e.g., financial, 
infrastructure) and limit the capacity of potential providers, along with potential 
reach and scalability (Aarons et al., 2012; Rogers, 2002; Lyon & Koerner, 2016). 
Thus, to leverage the potential benefits of briefer interventions, additional 
attention to other structural and design features is necessary to ensure the 
protocols being reinvented are responsive to issues relevant to readiness for large-
scale dissemination and implementation. 
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Concluding Comments 
Looking ahead, the future is bright for briefer, more streamlined EBIs for 
pediatric anxiety. There is reason for optimism, given the number of well-established and 
probably efficacious brief, non-pharmacological interventions for anxious that are 
available to clinicians and other service providers, expanding intervention options noted 
by Higa-McMillan et al. (2016). It is important to keep in mind, however, that 
earmarking a psychosocial intervention as well-established does not necessarily translate 
into policy or readiness for adoption, sustainability, or scaling-up. As articulated by 
Elliott and Mihalic (2004), Fagan and Mihalic (2003), Flay, Biglan, Boruch, Gonzales 
Castro, Gottfredson, et al. (2005), Greenberg et al. (2005), and Fixen et al. (2018), there 
need to be resources for adequate dissemination and implementation. Initial resources 
may include high quality training, monitoring and technical assistance, and disclosures 
about costs (e.g., staff training, on-site time, space, equipment, reproduction of materials; 
Chatterji et al., 2001; Foster et al., 2003; Lyon, Stanick, & Pullman, 2017). Over time, 
there needs to be ongoing communication between researchers and providers about the 
conditions under which the intervention is working, maintenance of program effects, 
booster sessions, availability of innovative efficiencies (e.g., digital health tools), and 
regular cost-benefit evaluation reports. Therefore, scaling-up evidence-based 
psychosocial interventions that are brief and thus more sustainable means having 
essential armamentaria in place so that anxious children and their families can live 
productive and happy lives.  
At the same time, it also is important to consider the pipeline in which these 
protocols are currently being developed, evaluated, and disseminated. It takes, on 
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average, 17 years for evidence-based programs to become “certified” as efficacious and 
considered for broad diffusion (Balas & Boren, 2000; Rotheram-Borus, Swendeman, & 
Chorpita, 2012); largely due to the research process. That is, becoming certified as 
efficacious often includes two years for development and pilot testing, five-years for an 
efficacy trial (evaluation under ideal or controlled conditions), an additional five-year 
efficacy trial (for intervention refinement and replication), and then five more years for 
effectiveness testing (under real-world conditions) (Rotheram-Borus et al., 2012; 
Schoenwald & Hoagwood, 2001). And, beyond the point of being deemed efficacious, 
there exists little to no infrastructure to disseminate EBIs at a large enough scale to 
achieve intended public health impact in ways that are responsive to the needs and 
realities of youth, families, providers, and delivery organizations. Thus, if we aim to 
realize the public health promise of evidence-based practices and reduce the incidence 
and prevalence of anxiety disorders in sustainable manner, prioritizing these research 
directions would likely greatly expand the availability and accessibility of EBIs, thus 
benefiting more youth, families, and communities.  
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Table 1. Criteria for Study Selection and Evidence-Based Status 
 
Design and Methods (M) 
 
M.1. Group design: Study involved a randomized controlled design 
M.2. Independent variable: Intervention was manualized or logical equivalent 
M.3. Population: Specified problems based on clearly delineated inclusion/exclusion 
criteria 
M.4. Dependent variable: Reliable and valid measures used to ascertain outcomes 
M.5. Analyses: Appropriate analytic approach with sufficient sample size to detect 
effects 
 
Evidence-Based Status Criteria (Level 1 to 5) 
 
Well-Established (Level 1) 
Effects demonstrated on most primary outcomes by showing: 
 
1.1a. Statistically significant superiority to pill, psychological placebo, or another 
active intervention 
OR 
1.1b. Equivalent (or not significantly different) to an already well-established 
intervention, 
AND 
1.1c. In at least two independent research settings and by two independent 
investigatory teams, 
AND 
1.2. M.1 to M.5 
 
Probably Efficacious (Level 2) 
Effects demonstrated for the intervention by showing: 
 
2.1. Statistically significant superiority to a waitlist or no intervention control, in at 
least two good experiments, 
OR 
2.2. Well-Established criteria except for 1.1c 
AND 
2.3. M.1 to M.5 
 
Possibly Efficacious (Level 3) 
Effects demonstrated for the intervention by showing: 
 
3.1 Statistically significant superiority to a waitlist or no intervention control, in at least 
one experiment, 
AND 
3.2. M.1 to M.5 
  60 
OR 
3.3 Statistically significant effects, in at least two clinical studies, with two or more 
studies meeting the M.2 to M.5. 
 
Experimental (Level 4) 
Effects demonstrated for the intervention by showing: 
 
4.1. Statistically significant effects, but not tested in an experiment 
OR 
4.2. Statistically significant effects, in at least one experiment, but no sufficient to meet 
Level 3 criteria 
 
Questionable (Level 5) 
Effects demonstrated for the intervention by showing: 
 
5.1. Inferiority to another intervention, waitlist, and/or control, 
OR 
5.2. No beneficial effects. 
Notes: Relevant to R.1, Kazdin and Bass found that a sample size of 12 per condition, 
with treatment vs. no-treatment main effect comparisons, yielded large effects while 
intervention versus placebo main effect comparisons yielded small to medium effects. 
Criteria from Silverman and Hinshaw (2008), Division 12 Task Force on Psychological 
Interventions’ reports (Chambless et al., 1996, 1998), Chambless and Hollon (1998), 
and Chambless and Ollendick (2001). Editorial revisions were made to the M criteria 
and Levels 1 to 5 to expand scope of interventions from treatments to also include 
preventive interventions; however, classification of interventions remained unaffected 
by our editorial revisions. 
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Table 2. RCTs Contributing to the Classification of Brief EBIs for Pediatric Anxiety 
Study Sample Characteristics Significant Program Effects Criteria 
Anxiety (n = 66) 
Hains 
(1992) 
[1] 
N = 25. Ages 15 to 16 
years. Mean age not 
reported. 0% girls. 
Randomized to individual 
plus group cognitive-
behavioral stress 
management intervention 
(CBSMI), individual plus 
group anxiety management 
training (AMS), or waitlist 
control.  
 
Intervention conditions did not 
differ from one another. At 
posttest and 3-week FU, CBSMI 
and AMS led to lower STAIC 
state anxiety, STAIC trait 
anxiety, STAXI trait anger, 
STAXI state anger, and RCADS 
depression than control.  
 
M.1 to 
M.4 
Kiselica et 
al. (1994) 
[2] 
N = 48. 9th grade students. 
Mean age not reported. 
46% girls. Top 12 highest 
scores in classroom on 
STAIC-T anxiety. 
Randomized to stress 
inoculation training or 
usual care.  
At posttest and 1-month FU, 
stress inoculation training led to 
lower STAIC trait anxiety than 
usual care. No other between-
group differences emerged on 
SOSI stress or GPA. Stress 
inoculation training led to lower 
SOSI stress at posttest and FU.  
 
M.1 to 
M.5 
Barrett et 
al. (2000) 
[3] 
N = 20. Ages 14 to 19 
years (M = 16.30). Former 
Yugoslavian Refugee in 
Australia. Randomized to 
group cognitive behavior 
therapy (GCBT) or waitlist 
control. 
 
At posttest, GCBT led to reduced 
YSR anxiety/ depression than 
control. GCBT led to lower YSR 
internalizing, SCAS anxiety, and 
ASP cognitive styles but 
between-group differences were 
not evident.  
 
M.1 to 
M.4 
Barrett et 
al. (2001) 
[4] 
N = 204. Ages 7 to 19 
years (M = 12.50). Non-
English-speaking 
Background in Australia. 
Randomized to GCBT or 
waitlist control.  
 
At posttest, GCBT led to more 
improvements in BHS future 
outlook/hopelessness, SEI school 
self-esteem, RSES self-esteem, 
and reductions in RCMAS 
anxiety than control. 
M.1 to 
M.5 
Ginsburg 
& Drake 
(2002) 
[5] 
N =12. Ages 14 to 17 years 
(M = 15.60). 83% girls. 
DSM GAD, Specific 
Phobia, SoP, SAD. 
Randomized to GCBT or 
attention control. 
At posttest, GCBT led to lower 
ADIS-C/P CSR severity and 
SCARED-C anxiety than control. 
GCBT led to lower SAS-A social 
anxiety, but between-group 
differences were not evident. 
M.1 to 
M.4  
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Heyne et 
al. (2002)  
[6] 
N = 61. Ages 7 to 14 years 
(M = 11.50). 46% girls. 
Met school refusal criteria 
as defined by Berg et al. 
(1969) and DSM GAD, 
Specific Phobia, SAD, 
SoP. Randomized to ICBT, 
ICBT plus parent teacher 
training (ICBT+PTT), or 
parent/teacher training 
(PTT) only. 
 
At posttest, ICBT+PTT and PTT 
led to higher school attendance 
than ICBT. ICBT+PTT also led 
to lower CBCL internalizing 
symptoms than ICBT at posttest. 
In addition, PTT led to 
significantly less FSSC-R fear of 
the unknown, RCMAS worry 
and oversensitivity, and RCMAS 
physiological anxiety than ICBT. 
Additional between-group 
differences were not evident for 
any outcome at posttest or 4.5-
month FU. All conditions led to 
lower FSSC-R fears, RCMAS 
anxiety, CDI depression, and 
higher SEQSS self-efficacy at 
posttest. At FU, ICBT+PTT led 
to lower FSSC-R fear and 
RCMAS worry/ oversensitivity, 
ICBT led to lower FSSC-R fear, 
RCMAS physiological 
complaints and higher SEQSS 
self-efficacy. At FU, 69% (across 
all conditions) no longer met 
ADIS-C/P CSR diagnostic 
criteria for any anxiety disorder.   
 
M.1 to 
M.5 
Muris et al. 
(2002)  
[7] 
N = 30. Ages 9 to 12 years 
(M = 10.00). 43% girls. 
RCADS ≥ 9 (boys) or 11 
(girls) anxiety symptoms 
and DSM GAD, Specific 
Phobia, SAD, SoP. 
Randomized to ICBT, 
emotional disclosure 
treatment (ED), or no 
treatment control. 
 
At posttest, ICBT led to lower 
RCADS anxiety, RCADS 
depression, STAIC trait anxiety 
than control and ED. At posttest, 
RCADS anxiety recovery rates 
were 80% in ICBT vs 40% in ED 
and 30% in control. 
 
M.1 to 
M.4 
Gallagher 
et al. 
(2004)  
[8] 
N = 23. Ages 8 to 11 years. 
Mean age not reported. 
52% girls. DSM SoP. 
Randomized to GCBT or 
waitlist control. 
At posttest, GCBT led to lower 
CBCL anxiety/ depression than 
control. At 3-week FU, GCBT 
led to lower SPAI-C social 
anxiety, RCMAS anxiety, CDI 
M.1 to 
M.4 
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depression, and CBCL 
anxiety/depression than control. 
No other between-group 
differences emerged on SASC-R 
social anxiety, CBCL social 
competence, CBCL activities, or 
CBCL school problems. Both 
GCBT and control led to lower 
SASC-R social anxiety at 
posttest and FU. 
 
Bernstein 
et al. 
(2005) 
[9] 
N = 61. Ages 7 to 11 years 
(M = 9.00). 66% girls. 53% 
girls. DSM GAD, Specific 
Phobia, SAD, SoP. 
Randomized to GCBT, 
GCBT plus parent training, 
or no-treatment control.   
At posttest, 3-, and 6-month FU, 
GCBT and GCBT plus parent 
training led to lower MASC-P 
anxiety, SCARED-P anxiety, 
ADIS-C/P CSR severity, and 
CGI functioning than control. 
Stronger pre to posttest changes 
were found for GCBT plus 
parent training than GCBT for 
CGI functioning. At 12-month 
FU, GCBT and GCBT plus 
parent training led to lower CSR 
severity ratings than control, with 
improvements in CGI 
functioning being maintained at 
3-year FU (Lee et al. 2016). 
 
M.1 to 
M.5 
Mifsud & 
Rapee 
(2005) 
[10] 
N = 425. Ages 8 to 11 
years (M = 9.5). 59% girls. 
RCMAS ≥ 18 RCMAS 
anxiety symptoms. 
Randomized to GCBT or 
waitlist control.  
At posttest and 4-month FU, 
GCBT led to lower RCMAS 
anxiety, SCAS anxiety, SCAS-P 
anxiety, CATS automatic 
thoughts, and TRF emotional and 
behavioral problems than control.  
 
M.1 to 
M.5 
Rapee et 
al. (2005) 
[11] 
N = 146. Ages 3 to 5 years 
(M = 3.9). 55% girls. 
STSC-approach subscale > 
30. Randomized to parent-
education intervention or 
assessment only control.  
 
Between-group differences were 
not evident for any outcome at 
posttest. Both parent-education 
intervention and control led to 
improvements in STSC-C/P 
temperament, TABC-R-P 
temperament, and behavioral 
inhibition measured via approach 
tasks. At 12-month FU, parent-
education intervention had fewer 
M.1 to 
M.5 
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ADIS-C/P CSR anxiety disorder 
diagnoses than control. At 11-
year FU, girls in the parent-
education intervention had lower 
SCAS-P anxiety, CALIS-C life 
interference, and fewer ADIS-
C/P anxiety disorder diagnoses 
than control and boys in the 
intervention condition (Rapee et 
al., 2013).   
 
Dadds & 
Roth 
(2008)  
[12] 
N = 734. Ages 3 to 7 years. 
Mean age not reported. 
47% girls. Randomized to 
parent-focused ICBT or no 
intervention control. 
At posttest, parent-focused CBT 
led to lower teacher reported 
SCBE child anxious-withdrawn 
and angry-aggressive behaviors 
and higher SCBE social 
competence than control. 
Between group differences were 
not evident at 7-month FU. 
M.1 to 
M.5 
Aune & 
Stiles 
(2009)  
[13] 
N = 1,439. Ages 12 to 14 
years. Mean age not 
reported. 52% girls. 
Randomized to GCBT or 
no intervention control. 
  
At posttest, GCBT led to lower 
SPAI-C social anxiety and 
SCARED anxiety than control.  
 
M.1 to 
M.5 
N = 190. Ages 12 to 14 
years. Mean age not 
reported. 52% girls. Post-
hoc subsample. SPAI-C ≥ 
18 social anxiety 
symptoms. Randomized to 
GCBT or no intervention 
control.  
 
At posttest, GCBT led to lower 
SPAI-C social anxiety and 
SCARED anxiety than control. 
M.1 to 
M.5 
Calear et 
al. (2009)  
[14] 
N = 1,477. Ages 12 to 17 
years. Mean age not 
reported. 56% girls. 
Randomized to internet-
delivered CBT (iCBT) or 
waitlist control.  
 
At posttest and 6-month FU, 
iCBT led to lower RCMAS 
anxiety than control.  
 
M.1 to 
M.5 
Ginsburg 
(2009) 
[15] 
N = 40. Ages 7 to 12 years 
(M = 8.94). 45% girls. 
Parents met DSM criteria 
for GAD, Specific Phobia, 
At posttest, 6-month, and 12-
month FU, family-focused ICBT 
led to lower ADIS-CSR severity 
and SCARED-P anxiety than 
M.1 to 
M.5 
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SAD, SoP. Randomized to 
parent-focused ICBT or 
waitlist control. 
control. At 12-month FU, family-
focused ICBT led to fewer ADIS 
anxiety disorder diagnoses than 
control (0% vs. 30%).  
 
Hunt et al. 
(2009) 
[16] 
N = 260. 9th grade students. 
Mean age and sex not 
reported. 43% girls. 
RCMAS >1 SD above 
mean of a normative 
sample. Randomized to 
GCBT or assessment only 
control.  
 
Between-group differences were 
not evident for any outcome at 
posttest, 2-year FU, and 4-year 
FU. Both GCBT and control led 
to lower RCMAS anxiety at 4-
year FU. 
 
M.1 to 
M.5 
Balle & 
Tortella-
Feliu 
(2010)  
[17] 
N = 92. Ages 11 to 17 
years. Mean age and sex 
not reported. CASI > 80th 
percentile for anxiety 
sensitivity. Randomized to 
GCBT, waitlist, or no 
intervention control. 
Between-group differences were 
not evident at posttest. Both 
GCBT and control conditions led 
to lower CASI anxiety sensitivity 
and SCAS-P anxiety symptoms. 
At 6-month FU, GCBT led to 
lower CASI anxiety sensitivity 
than controls. 
 
M.1 to 
M.5 
Khanna & 
Kendall 
(2010) 
[18] 
N = 49. Ages 7 to 13 years 
(M = 10.10). 33% girls. 
DSM GAD, Specific 
Phobia, SAD, SoP. 
Randomized to computer-
assisted CBT (CCAL), 
ICBT, or computer-assisted 
attention control.  
Intervention conditions did not 
differ from one another. At 
posttest and 3-month FU, CCAL 
and ICBT led to lower ADIS-C/P 
CSR severity than control. No 
other between-group differences 
emerged on CGAS functioning, 
MASC-C anxiety, or CDI-C 
depression. CCAL and ICBT 
demonstrated reductions in 
MASC-C anxiety and CDI-C 
depression at posttest.  
 
M.1 to 
M.5 
Miller et 
al. (2010)  
[19] 
N = 118. Ages 7 to 12 
years (M = 9.75). 50% 
girls. Randomized to 
GCBT or waitlist control.  
Between-group differences were 
not evident for any outcome at 
posttest. Both GCBT and control 
led to lower MASC anxiety and 
BASC-IC internalizing 
symptoms.  
 
M.1 to 
M.5 
N = 33. Ages 7 to 12 years 
(M = 9.75). 50% girls. 
At posttest, GCBT led to lower 
MASC anxiety than control. 
M.1 to 
M.5 
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Post-hoc subsample. 
MASC anxiety > 56. 
Randomized to GCBT or 
waitlist control. 
 
Pahl & 
Barrett 
(2010) 
[20] 
N = 263. Ages 4 to 6 years 
(M = 4.56). 48% girls. 
Randomized to GCBT or 
waitlist control. 
At posttest, GCBT led to lower 
BIQ-T behavioral inhibition and 
higher BERS-T social-emotional 
competence than control. No 
other between-group differences 
emerged on PAS anxiety, BIQ-P 
behavioral inhibition, or BERS-P 
social-emotional competence. 
GCBT led to lower PAS anxiety, 
BIQ-P behavioral inhibition, and 
higher BERS-P social-emotional 
competence at posttest and 12-
month FU.  
 
M.1 to 
M.5 
Bar Haim 
et al. 
(2011)  
[21] 
N = 34. Age 10 years (M = 
10.10). 71% girls. 
SCARED > 50th percentile 
for anxiety symptoms. 
Randomized to attention 
bias modification training 
(ABMt) or attention control 
training (ACT). 
 
At posttest, ABMt led to higher 
rates of disengagement from 
threat and were less vulnerable to 
the stress induced by the stressor 
task than ACT. No additional 
between-group differences were 
evident, with both ABMt and 
ACT having led to lower STAIC 
trait anxiety at posttest. 
 
M.1 to 
M.5 
Miller et 
al. 
(2011a1) 
[22] 
N = 191. Ages 9 to 12 
years (M = 10.1). 48% 
girls. MASC anxiety T-
score of ≥ 56. Randomized 
to GCBT or attention 
control. 
 
Between-group differences were 
not evident for any outcome at 
posttest, 5-month, or 17-month 
FU.  
 
M.1 to 
M.5 
N = 42. Ages 9 to 12 years 
(M = 10.1). Post-hoc 
subsample. MASC anxiety 
T-score of > 65. 
Randomized to GCBT or 
attention control. 
 
Between-group differences were 
not evident for any outcome at 
posttest, 5-month, or 17-month 
FU.  
M.1 to 
M.5 
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Miller et 
al. 
(2011a2) 
[23] 
N = 253. Ages 9 to 12 
years (M = 9.80). 54% 
girls. Randomized to 
GCBT or attention control. 
 
Between-group differences were 
not evident for any outcome at 
posttest or 17-month FU.  
 
M.1 to 
M.5 
N = 64. Ages 9 to 12 years 
(M = 9.80). Post-hoc 
subsample. MASC anxiety 
T-score of > 65. 
Randomized to GCBT or 
attention control. 
 
Between-group differences were 
not evident for any outcome at 
posttest or 17-month FU.  
M.1 to 
M.5 
Miller et 
al. (2011b) 
[24] 
N = 553. Ages 9 to 12 
years (M =9.77). 50% girls. 
Randomized to GCBT or 
waitlist control.  
 
Between-group differences were 
not evident. At posttest and 3-
month FU, GCBT led to lower 
MASC anxiety. 
 
M.1 to 
M.5 
Stallard et 
al. (2011)  
[25] 
N = 20. Ages 11 to 16 
years. Mean age and sex 
not reported. Seeking 
services at Tier 3 Child and 
Adolescent Mental Health 
Services with DSM GAD, 
Specific Phobia, SAD, SoP 
or mild-moderate 
depression. Randomized to 
computer-assisted CBT or 
waitlist control. 
No between-group analyses were 
conducted. Both computer-
assisted CBT and control led to 
improved RSEI self-esteem and 
SQC cognitive schemas. 
Computer-assisted CBT also led 
to lower SCAS social phobia 
SDQ-P emotional difficulties, 
SDQ-P hyperactivity, AWS 
depression, and improved SDQ-P 
total strengths and difficulties. 
Control also led to lower SCAS 
physical injury fears. 
 
M.1 to 
M.4 
Tillfors et 
al. (2011) 
[26] 
N = 19. Ages 15 to 21 
years (M = 16.50). 89% 
girls. DSM SoP. 
Randomized to iCBT or 
waitlist control.  
At posttest and 1-year FU, iCBT 
led to lower SPSQ-C social 
anxiety, LSAS-RS social anxiety, 
BAI anxiety, and MADRS-S 
depression than control.  
 
M.1 to 
M.4 
Attwood et 
al. (2012) 
[27] 
N = 13. Ages 10 to 12 
years (M = 10.6). 0% girls. 
Randomized to computer-
assisted CBT or computer 
gaming control. 
 
At posttest, computer-assisted 
CBT led to lower SCAS anxiety, 
SCAS social anxiety, and SCAS 
generalized anxiety than control. 
 
M.1 to 
M.4 
Eldar et al. 
(2012)  
N = 40. Ages 8 to 14 years 
(M = 9.84). 45% girls. 
At posttest, ABMt led to greater 
reductions in dot-probe task 
M.1 to 
M.5 
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[28] DSM GAD, Specific 
Phobia, SAD, SoP. 
Randomized to ABMt 
away from threat, placebo 
attention control training 
using ABMt stimuli, or 
placebo attention training 
using neutral stimuli. 
attentional bias and ADIS-IV-
C/P anxiety symptom counts 
compared to controls. At posttest, 
33% of children in the ABMt 
condition no longer met ADIS-
C/P CSR diagnostic criteria for 
any anxiety disorder, compared 
to 13.3% in the placebo 
condition, and 0% in the neutral 
placebo condition. No other 
between-group differences 
emerged on SCARED-anxiety or 
CDI-C depression, with all three 
conditions having led to lower 
SCARED-C anxiety and CDI-C 
depression. 
 
Ginsburg 
et al. 
(2012)  
[29] 
N = 32. Ages 8 to 12 years 
(M = 10.28). 63% girls. 
DSM GAD, Specific 
Phobia, SAD, SoP. 
Randomized to modular 
ICBT or usual care.  
Between-group differences were 
not evident for any outcome at 
posttest and 1-month FU. Both 
modular ICBT and usual care led 
to lower ADIS-C/P CSR anxiety 
severity, SCARED-C anxiety, 
and SDQ emotional difficulties, 
and higher CGAS functioning.  
 
M.1 to 
M.5 
McLoone 
& Rapee 
(2012) 
[30] 
N = 152. Ages 7 to 12 
years (M = 9.8). 62% girls. 
10% of SCAS scores for 
their age group. 
Randomized to school-
based GCBT, bibliotherapy 
w/o clinician support, or 
waitlist control.  
 
At posttest and 12-month FU, 
school-based GCBT and 
bibliotherapy w/o clinician 
support led to lower SCAS-P 
anxiety and CALIS life 
interference than control. 
 
M.1 to 
M.5 
Thirlwall 
et al. 
(2013)  
[31] 
N = 194. Ages 7 to 12 
years. Mean age not 
reported. 52% girls. DSM 
GAD, Specific Phobia, 
SAD, SoP. Randomized to 
full guidance parent-
delivered CBT, brief 
guidance parent-delivered 
CBT, or waitlist control. 
At posttest, full guidance parent-
delivered CBT led to lower 
CAIS-P interference and SMFQ 
low mood than brief guidance 
parent-delivered CBT and 
control. At posttest, participants 
in both treatment conditions were 
85% more likely to have 
recovered from their ADIS-C/P 
CSR principal anxiety disorder 
M.1 to 
M.5 
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than control, with full guided 
parent-delivered CBT leading to 
higher diagnostic recovery (50%) 
than brief guided parent-
delivered CBT (39%). ADIS-C/P 
CSR diagnostic recovery rates at 
6-month FU were comparable for 
both treatment conditions (76% 
for full guided, 71% for brief 
guided). Improvements for the 
intervention conditions were 
maintained at 3- to 5-year FU 
(Brown et al., 2017). 
  
Waters et 
al. (2013)  
[32] 
N = 37. Ages 7 to 13 years 
(M = 9.60). 65% girls. 
DSM GAD, Specific 
Phobia, SAD, SoP. 
Randomized to ABMt-
attention-towards-positive 
(ABMt-ATP) or ABMt 
attention training control 
(ABMt-ATC). 
At posttest, ABMt-ATP led to 
lower ADIS-C/P CSR severity 
and higher attentional bias 
towards positive stimuli (via dot-
probe task) than control. At 
posttest, 50% in ABMt-ATP no 
longer met ADIS-C/P CSR 
diagnostic criteria for principal 
anxiety disorder compared to 8% 
in control. No other between-
group differences emerged on 
SCAS anxiety, SCAS-P anxiety, 
or CES-DC depression, with both 
conditions having led to lower 
SCAS anxiety, SCAS-P anxiety, 
and CES-DC depression at 
posttest.  
 
M.1 to 
M.5 
Collins et 
al. (2014) 
[33] 
N = 317. Ages 9 to 10 
years. Mean age not 
reported. 45% girls. 
Randomized to 
psychologist-led GCBT, 
teacher-led GCBT, or usual 
care.   
Intervention conditions did not 
differ from one another at 
posttest. At posttest and 6-month 
FU, psychologist-led GCBT and 
teacher-led GCBT led to lower 
SCAS anxiety, CSI avoidance 
coping, and higher CSI problem 
solving coping and CSI social 
coping than control. At 6-month 
FU, psychologist-led GCBT led 
to lower SCAS anxiety than 
teacher-led GCBT and control, 
whereas teacher-led GCBT led to 
M.1 to 
M.5 
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lower CSI avoidant coping was 
lower in teacher-led GCBT than 
psychologist-led GCBT and 
control.  
 
Donovan 
& March 
(2014)  
[34] 
N = 52. Ages 3 to 6 years 
(M = 4.08). 54% girls. 
DSM GAD, Specific 
Phobia, SAD, SoP. 
Randomized to parent 
focused iCBT or waitlist 
control.  
At posttest, 6-month, and 12-
month FU, iCBT led to lower 
PAS anxiety, CBCL 
internalizing, and higher CGAS 
functioning than control. At 
posttest, ADIS-C/P CSR 
diagnostic recovery rates were 
39.1% in iCBT and 25.9% in 
control; with iCBT ADIS-C/P 
CSR recovery rates improving to 
70.6% in iCBT at 12-month FU.  
 
M.1 to 
M.5 
Stallard et 
al. (2014) 
[35] 
N = 1,362. Ages 9 to 10 
years. Mean age not 
reported. 51% girls. 
Randomized to school 
staff-led GCBT, health 
facilitator-led GCBT, or 
personal social and health 
education (PSHE) control.   
At 12-month FU, health 
facilitator-led and school staff-
led GCBT led to lower RCADS-
C anxiety than control, with more 
pronounced changes occurring 
for those in school staff GCBT. 
At FU, health facilitator GCBT 
led to lower RCADS separation 
anxiety than school staff GCBT 
and control (Skryabina et al., 
2016). 
M.1 to 
M.5 
N = 99. Ages 9 to 10 years. 
Mean age not reported. 
Post-hoc subsample. ≥ 49 
on RCADS anxiety. 
Randomized to school 
staff-led GCBT, health 
facilitator-led GCBT, or 
personal social and health 
education (PSHE) control. 
   
Between-group differences were 
not evident for any outcome at 
posttest or 3-month FU. Both 
school staff-led and health 
facilitator-led GCBT led to lower 
RCADS-C anxiety. 
M.1 to 
M.5 
Wong et al. 
(2014)  
[36] 
N = 976. Ages 14 to 16 
years. Mean age not 
reported. 70% girls. 
Randomized to iCBT for 
anxiety, iCBT for 
depression, or usual care. 
Intervention conditions were not 
different from one another. At 
posttest, iCBT for anxiety led to 
reductions in GAD-7 generalized 
anxiety than control. iCBT for 
depression led to reductions in 
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PHQ-5 depression than usual 
care. 
 
Rodgers & 
Dunsmuir 
(2015) 
[37] 
N =62. Ages 12 to 13 
years. Mean age not 
reported. 69% girls. 
Randomized to GCBT or 
waitlist control.  
At posttest and 4-month FU, 
GCBT led to lower SCAS and 
SCAS-P anxiety than control. No 
other between-group differences 
emerged on CRS school 
adjustment, with both GCBT and 
control having led to 
improvements in CRS school 
adjustment. 
 
M.1 to 
M.5 
Ginsburg 
et al. 
(2015) 
[38] 
N = 136. Ages 6 to 13 
years (M = 8.70). Parents 
met DSM criteria for GAD, 
Specific Phobia, SAD, 
SoP. Randomized to 
family-focused ICBT or 
information-monitoring 
control. 
At posttest, 6-month, and 12-
month FU, family-focused ICBT 
led to reduced ADIS-CSR 
severity than control. At 12-
month FU, family-focused ICBT 
led to fewer ADIS anxiety 
disorder diagnoses than control 
(5.26% vs. 30.65%). Over time, 
family-focused ICBT also led to 
lower SCARED-P anxiety, 
CBCL anxiety/depressive 
symptoms, and CBCL behavior 
problems than control (Pella et 
al., 2016). 
 
M.1 to 
M.5 
Waters et 
al. (2015) 
[39] 
N = 59. Ages 6 to 17 years 
(M = 8.75). 53% girls. 
DSM GAD, Specific 
Phobia, SAD, SoP. 
Randomized to ABMt or 
waitlist control.  
At posttest and 6-month FU, 
ABMt led to lower ADIS-C/P 
CSR severity, SCAS-P anxiety, 
SMFQ-P strengths and 
difficulties, CBCL internalizing, 
and higher CGAS functioning 
than control. At posttest, 35% no 
longer met ADIS-C/P CSR 
diagnostic criteria for principal 
anxiety disorder for ABMt vs. 
7% in control. 
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Whiteside 
et al. 
(2015)  
[40] 
N = 14. Ages 7 to 14 (M = 
10.20). 71% girls. DSM 
GAD, Specific Phobia, 
SAD, SoP. Randomized to 
ICBT or parent-coached 
exposure therapy (PC-
Exp). 
At posttest and 3-month FU, PC-
Exp led to lower CBCL 
internalizing, CBCL 
externalizing, PARS anxiety, 
ADIS CSR severity, CGI 
severity, SCAS anxiety, SCAS-P 
anxiety, CSDS-P disability, and 
CATS negative cognitions than 
ICBT. 
 
M.1 to 
M.4 
Calear et 
al. (2016a)  
[41] 
N = 1,767. Ages 12 to 18 
years (M = 14.86). 75% 
girls. Randomized to 
school supported iCBT, 
health service supported 
iCBT (e-GAD HS), or 
waitlist control. 
Intervention conditions did not 
differ from one another. At 
posttest and 6-month FU, school 
supported iCBT led to lower 
SAS-A social anxiety, GAD-Y 
generalized anxiety, and higher 
WEMWBS psychological 
wellbeing than control. At 6-
month FU, e-GAD HS led to 
higher WEMWBS wellbeing 
than control. No between-group 
differences were evident for any 
outcome at 12-month FU. 
 
M.1 to 
M.5 
Calear et 
al. (2016b)  
[42] 
 
N = 225. Ages 12 to 18 
years (M = 14.86). 75% 
girls. Randomized to 
school-based iCBT or 
waitlist control. 
No between-group differences 
were evident for any outcome at 
posttest or 3-month FU.  
M.1 to 
M.5 
Fitzgerald 
et al. 
(2016) 
[43] 
N = 130. Ages 15 to 18 
years (M = 15.94). 57% 
girls. SPAI-C ≥ 24. 
Randomized to ABMt or 
attention control training 
(ACT).  
 
Between-group differences were 
not evident at post-test or 4-
month FU. Both ABMt and ACT 
led to lower SPAI-C social 
anxiety and SCARED anxiety. 
 
M.1 to 
M.5 
Infantino et 
al. (2016)  
[44] 
N = 24. Ages 5 to 11 years 
(M = 7.46). 54% girls. 
DSM GAD, Specific 
Phobia, SAD, SoP. 
Randomized to audio-
based CBT or waitlist 
control. 
At posttest and 3-month FU, 
audio-based CBT led to lower 
ADIS-C/P CSR severity, SCAS 
anxiety, and SCAS-P anxiety 
than control. At posttest, ADIS-
C/P CSR diagnostic recovery 
rates for principal disorder were 
58.3% for audio-based CBT and 
16.7% for control. At FU, 
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diagnostic recovery rates for 
audio-based CBT was 66.67%.  
 
Morgan et 
al. (2016)  
[45] 
N = 51. Ages 3 to 6 years 
(M = 4.75). 49% girls. 
STSC > 30. Randomized to 
parent-focused iCBT with 
clinician support or parent-
focused iCBT without 
clinician support.  
Intervention conditions did not 
differ from one another. At 
posttest, both conditions led to 
lower PAS-R anxiety, SDQ 
emotional difficulties, OAPA 
number of child anxiety 
diagnoses, and CALIS-PV life 
interference of anxiety. 
 
M.1 to 
M.5 
Pergamin-
Hight et al. 
(2016)  
[46] 
N = 67. Ages 6 to 18 years 
(M = 12.67). 57% girls. 
DSM SAD. Randomized to 
ABMt or ACT.  
Between-group differences were 
not evident. Both ABMt and 
ACT led to lower ADIS-C/P 
social anxiety severity, SPAI-C 
social anxiety, dot probe 
response latencies, and higher 
dot probe accuracy at post and 3-
month FU. 
 
M.1 to 
M.5 
Pophilat et 
al. (2016) 
[47] 
N = 206. Ages 6 to 9 years. 
Mean age not reported. 
51% girls. Randomized to 
GCBT or usual care control 
(health education classes). 
 
At posttest, GCBT led to lower 
SCAS-P anxiety. No other 
between-group differences 
emerged. Both conditions led to 
lower ACES emotional skills.  
 
M.1 to 
M.5 
Ruttledge 
et al. 
(2016) 
[48] 
N = 709. Ages 9 to 13 
years (M = 10.83). 51% 
girls. Randomized to 
GCBT or usual care control 
(health education classes). 
 
A posttest, GCBT led to 
improved BSC-Y self-concept, 
CES coping efficacy, and SCS 
school connectedness. GCBT 
also led to lower SCAS anxiety, 
however change was not 
significantly different than 
control. 
 
M.1 to 
M.5 
Scholten et 
al. (2016) 
[49] 
N = 139. Ages 11 to 15 
years (M = 13.27). 65% 
girls. SCAS ≥ 1 SD above 
the mean total anxiety 
symptoms or ≥ 1 SD above 
the mean on two SCAS 
subscales. Randomized to 
Biofeedback w/ relaxation 
Linear change of the top scoring 
SCAS subscale from pretest to 
posttest to FU was greater for 
Dojo than control. No between-
group differences emerged for 
SCAS total anxiety. 
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training video game (Dojo) 
or control video game. 
 
Schoneveld 
et al. 
(2016)  
[50] 
N = 136. Ages 7 to 13 
years (M = 9.95). 55% 
girls. SCAS ≥ 1 SD above 
the mean total anxiety 
symptoms or ≥ 1 SD above 
the mean on two SCAS 
subscales. Randomized to 
neurofeedback w/ 
exposures and ABMt video 
game (Mindlight) or 
control video game. 
 
Between-group differences were 
not evident at posttest and 3-
month FU. Both Mindlight and 
control led to lower SCAS and 
SCAS-P anxiety. 
M.1 to 
M.5 
Vigerland 
et al. 
(2016) 
[51] 
N = 93. Ages 8 to 12 years 
(M = 10.10). 51% girls. 
DSM GAD, PD, SAD, 
SoP, or Specific Phobia. 
Randomized to internet-
delivered CBT with 
therapist-support or waitlist 
control.   
At posttest, internet-delivered 
CBT led to lower ADIS-C/P 
CSR severity, SCAS-P anxiety, 
and improved CGAS functioning 
than control, with ADIS-C/P 
CSR severity and CGAS 
functioning improvements 
maintained at 3-month FU. No 
other between-group differences 
emerged on SCAS anxiety or 
QOLI-C quality of life. Internet-
delivered CBT led to reduced 
SCAS anxiety and QOLI-C 
quality of life at posttest. 
 
M.1 to 
M.5 
Ahlen et al. 
(2017) 
[52] 
N = 695. Ages 8 to 11 
years (M = 9.60). 48% 
girls. Randomized to 
GCBT or waitlist control. 
 
Between-group differences were 
not evident for any outcome at 
posttest and 12-month FU. 
 
M.1 to 
M.5 
Cobham et 
al. (2017) 
[53] 
N = 61. Ages 7 to 14 years 
(M = 9.30). 49% girls. 
DSM Specific phobia, 
SAD, GAD, or SoP. 
Randomized to parent-
focused GCBT or waitlist 
control.  
At posttest, 3-, 6-, and 12-month 
FU, parent-focused intervention 
led to lower ADIS-C/P CSR 
severity, SCAS-P anxiety, SCAS 
anxiety, and CBCL internalizing 
than control. At posttest, 64.5% 
in parent-focused intervention 
were free from principal anxiety 
disorder vs. 16.2% in control 
based on ADIS-C/P CSR 
M.1 to 
M.5 
  75 
criterion. Parent-focused 
intervention ADIS-C/P CSR 
recovery rates improved to 84% 
at 12-month FU. 
 
Creswell et 
al. (2017) 
[54] 
 
N = 136. Ages 5 to 12 (M = 
9.21). 53% girls. Referred 
to mental health clinic for 
anxiety-related 
impairments. Randomized 
to brief guidance parent-
delivered CBT or solution 
focused brief therapy 
(SFBT) 
Between-group differences were 
not evident for any outcome at 
posttest or 3-month FU. Both 
brief guidance parent-delivered 
CBT and SFBT led to higher 
CGI improvement scores and 
lower KFQ-C fears, SCAS 
anxiety, SCAS-P anxiety, and 
ADIS-C/P CSR. 
 
M.1 to 
M.5 
De Voogd 
et al. 
(2017) 
[55] 
N = 108. Ages 11 to 19 
years (M = 14.45). 67% 
girls. SCARED > 16 
anxiety symptoms and/or 
CDI > 7 depressive 
symptoms. Randomized to 
internet-based visual search 
ABMt (VS-ABMt), VS 
placebo-training, or no 
intervention control.  
At posttest, VS-ABMt led to 
lower EVST attentional bias and 
Recognition Task interpretation 
bias than controls. No other 
between-group differences 
emerged on SCARED anxiety, 
CDI-C depression, RSES self-
esteem, PTQ perseverative 
thinking, and SDQ-P strengths 
and difficulties, with all 
conditions having led to 
improvements in these outcomes 
at posttest and 6-month FU. 
 
M.1 to 
M.5 
Kato & 
Shumizu 
(2017) 
[56] 
 
N = 74. Ages 8 to 9 years. 
Mean age not reported. 
43% girls. Randomized to 
GCBT or no intervention 
control.  
At posttest, GCBT led to lower 
SCAS-P anxiety. No other 
between-group differences 
emerged on SCAS anxiety, 
DSRS-depression, Hope, or 
SDQ-P total difficulties. 
 
M.1 to 
M.5 
Morgan et 
al. (2017) 
[57] 
N = 433. Ages 3 to 6 years 
(M = 4.80). 53% girls. 
STSC > 30. Randomized to 
parent-focused iCBT (with 
clinician support as 
needed) or waitlist control.  
At posttest, parent-focused 
internet-based CBT led to lower 
PAS-R anxiety, CALIS life 
interference, and fewer PAS-R 
anxiety disorder diagnoses than 
control (40% vs. 54%, 
respectively). 
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Schoneveld 
et al. 
(2017)  
[58] 
N = 174. Ages 7 to 12 
years (M = 9.97). 59% 
girls. Randomized to 
cognitive-behavioral 
neurofeedback training 
video game video game 
(Mindlight) or GCBT. 
SCAS ≥ 1 SD above the 
mean total anxiety 
symptoms or ≥ 1 SD above 
the mean on two SCAS 
subscales.  
 
Between-group differences were 
not evident. Both Mindlight and 
GCBT led to lower SCAS and 
SCAS-P anxiety at posttest, 3-
month and 6-month FU.  
 
M.1 to 
M.5 
Weersing 
et al. 
(2017)  
[59] 
N = 185. Ages 8 to 17 (M = 
11.30). 58% girls. DSM 
GAD, Specific Phobia, 
SAD, SoP. Randomized to 
brief behavioral therapy 
(BBT) or assisted referral 
to care (ARC). 
 
At posttest, BBT led to lower 
CGI severity, PARS anxiety, 
improvements in CGAS 
functioning, and higher rates of 
CGI clinical improvement 
(56.8% vs. 28.2%) than ARC.  
 
M.1 to 
M.5 
Bayer et al. 
(2018) 
[60] 
N = 545. Ages 3 to 6 years 
(M = 4.55). 48% girls. 
Australian Temperament 
Project approach/inhibition 
> 30. Randomized to 
parent-focused GCBT or 
treatment as usual control 
(access to community 
mental health services). 
 
Between-group differences were 
not evident. Both parent-focused 
GCBT and control led to lower 
SDQ internalizing symptoms and 
fewer DSM anxiety disorder 
diagnoses based on ADIS-C/P 
criteria. 
M.1 to 
M.5 
Chavira et 
al. (2018) 
[61] 
N =31. Ages 8 to 13 years 
(M = 11.25). Mean age and 
sex not reported. DSM 
Specific phobia, SAD, 
GAD, or SoP. Randomized 
to parent-mediated CBT 
bibliotherapy telephone-
delivered, therapist-assisted 
bibliotherapy or parent-
mediated CBT 
bibliotherapy minimal 
contact, self-directed. 
 
At posttest, ADIS-C/P CSR 
recovery rates were 50% in 
telephone-therapist and 36% for 
self-directed. 
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Liu et al. 
(2018)  
[62] 
N = 84. Ages 9 to 12 years. 
Mean age and sex not 
reported. Met criteria for 
behavioral inhibition per 
BIQ. Randomized to ABMt 
or attention control 
training. 
At posttest, ABMt led to lower 
C-DISC-IV separation anxiety 
than control. ABMt also led to 
reduced amygdala and insulate 
activation and enhanced 
activation in ventrolateral 
prefrontal cortex relative to 
control via fMRI data. 
 
M.1 to 
M.5 
Ollendick 
et al. 
(2018)  
[63] 
N = 58. Ages 12 to 16 
years (M = 14.29). 71% 
girls. DSM SAD. 
Randomized to ABMt or 
ACT. 
At posttest, ABMt led to lower 
SCARED-C social anxiety than 
control. No other between-group 
differences emerged on 
SCARED-P social anxiety, 
EATQ-R-P attention control, or 
dot probe threat bias. Both ABMt 
and control led to lower 
SCARED-P social anxiety at 
posttest. 
 
M.1 to 
M.5 
Schleider 
& Weisz 
(2018)  
[64] 
N = 96. Ages 12 to 15 
years (M = 13.33) 55% 
girls. RCADS-P ≥ 84th 
percentile, has school-
based accommodations for 
internalizing symptoms, or 
sought treatment for 
anxiety in past 3 years. 
Randomized to computer-
based growth mindset 
intervention (GMI) or 
computer-based 
supportive-therapy. 
 
GMI led to lower CDI-P 
depression, SCARED-P anxiety, 
PCSC behavioral control, and 
CDI-C depression than 
computer-based supportive-
therapy. 
M.1 to 
M.5 
Suveg et 
al. (2018) 
[65] 
N = 92. Ages 7 to 12 years. 
Mean age not reported. 
42% girls. DSM GAD, 
SAD, SoP. Randomized to 
emotion-focused CBT 
(ECBT) or ICBT.   
Intervention conditions did not 
differ from one another. At 
posttest, both ECBT and ICBT 
led to lower ERC emotion 
regulation, ERC emotion 
dysregulation, ERC anger 
regulation, CEMS anger, 
sadness, and worry 
dysregulation, ADIS-C/P CSR 
severity, and CGI severity. At 
posttest, 72% in ECBT and 74% 
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in ICBT no longer met ADIS-IV 
diagnostic criteria for their 
principal anxiety disorder.  
 
Pina et al. 
(In Press)  
[66] 
 
N = 109. Ages 8 to 12 (M = 
9.64). 78% girls. SCAS ≥ 
42 anxiety symptoms. 
Randomized to GCBT with 
social skills training or 
active control. 
 
At 12-month FU, GCBT led to 
higher SEQSS self-efficacy for 
managing anxiety, SSIS-RS 
social competence, and lower 
CNCEQ cognitive interpretation 
biases than control. 
 
M.1 to 
M.5 
Phobias (n = 10) 
Sheslow 
(1982) 
[67] 
N = 32. Ages 4 to 5 years. 
Mean age not reported. 
50% girls. Darkness phobia 
as measure by < 8 seconds 
of darkness tolerance. 
Randomized to graduated 
exposure, verbal coping 
skills, graduated exposure 
plus verbal coping skills, or 
contact-only control. 
 
At posttest, graduated exposure 
condition and graduated 
exposure plus verbal coping 
skills conditions led to improved 
BAT dark tolerance than verbal 
coping skills and control, with 
more pronounced improvements 
occurring for graduated exposure 
condition. 
 
M.1 to 
M.4 
Menzies & 
Clark 
(1993)  
[68] 
N = 48. Ages 3 and 8 years 
(M = 5.50). BRS < 15 and 
water phobic (no DSM 
diagnosis). Randomized to 
in vivo exposure plus 
vicarious exposure (IVVE), 
vicarious exposure (VE), in 
vivo exposure (IVE), or 
assessment only control. 
At posttest, IVVE and IVE led to 
lower CWP water phobia, PCWP 
water phobia, OR phobic 
reactions, and greater 
improvements in BRS approach 
behavior and ability than control. 
At FU, IVVE, VE, and IVE led 
to further reductions in OR 
phobic reactions, and 
improvements in BRS approach 
behavior and ability than control. 
At FU, IVE demonstrated poorer 
effect maintenance and 
improvement on all outcomes 
than IVVE.  
 
M.1 to 
M.5 
Cornwall 
et al. 
(1996)  
[69] 
N = 24. Ages 7 to 10 years 
(M = 8.25). DSM Specific 
Phobia (darkness). 
Randomized to individual 
emotive imagery therapy 
(EAT) or waitlist control.  
At posttest and FU, EAT led to 
improvements in behavioral 
responses to darkness tolerance 
and lower FSSC-R fears, 
RCMAS anxiety, DFBQ 
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 darkness fear behavior than 
control.  
 
Muris et al. 
(1998)  
[70] 
N = 28. Ages 8 to 17 years 
(M = 12.58). 100% girls. 
DSM Specific Phobia 
(spiders). Randomized to 
EMDR, in vivo exposure 
(IVE), or computerized 
exposure control. 
 
At posttest and FU, IVE led to 
lower SPQ-C spider fear, SAM 
fear/arousal, BAT state anxiety, 
and BAT spider avoidance than 
EMDR and control. At posttest, 
EMDR led to lower SPQ-C 
spider fear than control.  
 
M.1 to 
M.4 
Dewis et 
al. (2001)  
[71] 
N = 28. Ages 10 to 17 
years. Mean age not 
reported. 64% girls. DSM 
Specific Phobia (spiders). 
Randomized to live graded 
exposure (LGE), computer-
aided vicarious exposure 
(CAVE), or waitlist 
control.  
At posttest and 1-month FU, 
LGE and CAVE had lower SPQ-
C spider phobia, PT phobic 
severity, BAT approach 
avoidance, and SUDS than 
control. At posttest, LGE 
improved more than CAVE on 
SPQ-C and SUDS and led to 
greater reductions in SPQ-C 
spider phobia and PT phobic 
severity than CAVE at FU.  
 
M.1 to 
M.4 
Ost et al. 
(2001)  
[72] 
N = 60. Ages 7 to 17 years 
(M = 11.70). 61% girls. 
DSM Specific Phobia. 
Randomized to child only 
one session treatment for 
specific phobia (OST), 
parent present OST, or 
waitlist control. 
At posttest and 1-year FU, child 
only OST and parent present 
OST led to lower BAT avoidance 
than waitlist control, with greater 
improvements emerging for child 
only OST. No other between-
group differences emerged on 
FSSC-R fears, RCMAS anxiety, 
CASI anxiety sensitivity, STAIC 
trait anxiety, STAIC state 
anxiety, and CDI depression. 
Both child-only OST and parent 
present OST led to lower FSSC-
R fear, RCMAS anxiety, STAIC 
anxiety, and CASI anxiety 
sensitivity at post and FU. 
 
M.1 to 
M.5 
Ollendick 
et al. 
(2009)  
[73] 
N = 196. Ages 7 to 16 
years (M = 11.00). 55% 
girls. DSM Specific 
Phobia. Randomized to 
OST, education support 
At posttest, OST led to lower 
BAT SUDS and ADIS-C/P CSR 
than EST and control. At 6-
month FU, OST led to lower 
ADIS-C/P CSR severity than 
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treatment (EST), or waitlist 
control. 
EST and control. Both OST and 
EST led to lower CBCL 
anxiety/depression, MASC 
anxiety, and FSSC-R fears than 
control at posttest and FU; OST 
and EST did not differ from one 
another for these outcomes. At 
posttest, ADIS-C/P CSR 
diagnostic recovery rates were 
55% in OST, 23% in EST, and 
2% in control; recovery rates 
were similar at FU (52% in OST 
and 21% in EST).  
 
Flatt & 
King 
(2010)  
[74] 
N = 43. Ages 7 to 17 years 
(M = 11.23). 60% girls. 
DSM Specific Phobia. 
Randomized to OST, 
psychoeducation, or 
waitlist control. 
Intervention conditions did not 
differ from one another. At 
posttest and 1-year FU, OST and 
Psychoeducation led to lower 
BAT approach avoidance and 
FSSC-II fearfulness, as well as 
higher SEQ-SP self-efficacy than 
control.  
 
M.1 to 
M.5 
Waters et 
al. (2014)  
[75] 
N = 37. Ages 6 to 17 years 
(M = 10.56) 57% girls. 
DSM Specific Phobia. 
Randomized to Attention 
training towards positive 
stimuli plus OST 
(ATP+OST) or attention 
control training plus OST 
(ACT+OST). 
At posttest and 3-month FU, 
ATP+OST led to lower danger 
expectancies to fear stimuli and 
greater bias towards positive 
stimuli at posttest than 
ACT+OST. No other between-
group differences emerged on 
SCAS anxiety, SCAS-P anxiety, 
and SMFQ-C/P depression, with 
both ATP+OST and ACT+OST 
having led to lower SCAS 
anxiety, SCAS-P anxiety, and 
SMFQ-C/P depression at posttest 
and FU.   
 
M.1 to 
M.5 
Ollendick 
et al. 
(2015)  
[76] 
N = 97. Ages 6 to 15 years. 
Mean age not reported. 
52% girls. DSM Specific 
Phobia. Randomized to 
OST or parent-augmented 
OST (A-OST). 
Intervention conditions did not 
differ from one another at 
posttest or 1-month FU. Both 
OST and A-OST led to lower 
ADIS-C/P CSR severity and 
higher PIR and CIR anxiety 
improvement. At 6-month FU, 
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OST resulted in marginally 
superior ADIS-C/P diagnostic 
recovery ratings than A-OST 
(67.39 % for OST and 49.02% 
for A-OST). 
 
Notes: ACES = Assessment of Children’s Emotional Skill; ADIS-C/P = Anxiety 
Disorders Interview Schedule for DSM-IV; ADIS-C/P CSR =Clinician Severity 
Rating; ASP = Ambiguous Situations Protocol; AWS = Adolescent Wellbeing Scale; 
BAI = Beck Anxiety Inventory; BASC-PRS = Behavior Assessment System for 
Children–Parent Rating Scales; BAT = Behavioral Assessment Test; BERS-P = 
Behavioral and Emotional Rating Scale (Parent); BERS-T = Behavioral and Emotional 
Rating Scale (Teacher); BHS = Beck Hopelessness Scale; BIQ = Behavioral Inhibition 
Questionnaire; BRS = Behavior Response Scale; BSC-Y = Beck Self-Concept 
Inventory for Youth; C-DISC-IV= Diagnostic Interview Schedule for Children; CALIS 
= Child Anxiety Life Interference Scale; CALIS-P = Child Anxiety Life Interference 
Scale (Parent); CALIS-PV-P = Child Anxiety Life Interference Scale – Preschool 
Version (Parent); CASI = Child Anxiety Sensitivity Index; CATS = Children's 
Automatic Thoughts Scale; CBCL = Child Behavior Checklist; CDI = Children’s 
Depression Inventory; CEMS = Children’s Emotion Management Scales; CES = 
Coping Efficacy Scale; CES-DC = Center for Epidemiological Studies Depression 
Scale; CGAS = Children’s Global Assessment Scale; CGI = Clinical Global 
Impressions; CIR = Child Improvement Rating; CNCEQ = Children’s Negative 
Cognitive Error Questionnaire; CRS = Child Rating Scale; CSDS-P = Child Sheehan 
Disability Scale (Parent); CSI = Coping Strategy Indicator; CWP = Water Phobia 
Survey Schedule; DFBQ = Darkness Fear Behavior Questionnaire; DSRS-C = 
Depression Self Rating Scale for Children; EATQ-R-P = Early Adolescent 
Temperament Questionnaire-Revised Short Form; ERC = Emotion Regulation 
Checklist; FSSC-R = Fear Survey Schedule for Children-Revised; GAD = Generalized 
Anxiety Disorder; GAD-7 = Generalized Anxiety Disorder - Seven item scale; Hope = 
Children’s Hope Scale; KFQ-C = Koala Fear Questionnaire – child report; LSAS - RS 
= Liebowitz Social Anxiety Scale-Revised; MADRS-S = Montgomery-Asberg 
Depression Rating Scale-Self Report; MASC = Multidimensional Anxiety Scale for 
Children; MASC-P = Multidimensional Anxiety Scale for Children (Parent); MES = 
Motivation and Engagement Scale; OAPA = Online Assessment of Preschool Anxiety; 
OR = Overall Reaction; PAS = Preschool Anxiety Scale; PAS-R = Preschool Anxiety 
Scale-Revised; PCSC = Perceived Control Scale for Children; PCWP = Water Phobia 
Survey Schedule (Parent); PHQ = Patient Health Questionnaire; PIR = Parent 
Improvement Rating; PT = Phobic Target; PTQ = Perseverative Thinking 
Questionnaire; QOLI-C Quality of Life Inventory-Child Version; RCADS = Revised 
Children's Anxiety and Depression Scale; RCMAS = Revised Children’s Manifest 
Anxiety Scale; RSEI = Rosenberg Self-Esteem Inventory; RSES = Rosenberg Self-
Esteem Scale; RTAS = Revised Test Anxiety Scale; SAD = Separation Anxiety 
Disorder; SAM = Self-Assessment Manikin; SAS-A = Social Anxiety Scale for 
Adolescents-Avoidance;  SASC-R = Social Anxiety Scale for Children-Revised; 
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SCARED = Screen for Child Anxiety Related Emotional Disorders; SCARED-P = 
Screen for Child Anxiety Related Emotional Disorders (Parent); SCAS = Spence 
Children’s Anxiety Scale;  SCAS-P = Spence Children’s Anxiety Scale SCAS-P 
(Parent); SCBE = Social Competence and Behavior Evaluation; SCS = School 
Connectedness Scale; SDQ-P = Strengths and Difficulties Questionnaire (Parent); SEI 
= Self Esteem Inventory; SEQ-SP Self-Efficacy Questionnaire for Specific Phobias; 
SEQSS = Self Efficacy Questionnaire for School Situations; SMFQ = Short Mood and 
Feelings Questionnaire; SMFQ-P = Short Mood and Feelings Questionnaire (Parent); 
SoP = Social Phobia; SOSI = Symptoms of Stress Inventory; SPAI-C = Social Phobia 
and Anxiety Inventory;  SPQ-C = Spider Phobia Questionnaire for Children; SPSQ-C 
= Social Phobia Screening Questionnaire for Children; SQC = Schema Questionnaire 
for Children; SSIS-RS = Social Skills Improvement System-Rating Scales;  STAIC = 
State-Trait Anxiety Inventory for Children; STAXI = State Trait Anger Expression 
Inventory; STSC = Short Temperament Scale for Children; STSC-P = Short 
Temperament Scale for Children (Parent); SUDS = Subjective Units of Distress; 
TABC-R-P = Temperament Assessment Battery for Children-Revised (Parent); TASC 
= Test Anxiety Scale for Children; TRF = Teacher’s Report Form; WEMWBS = 
Warwick-Edinburgh Mental Wellbeing Scale; YSR = Youth Self Report 
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Table 5. Pre to Post Moderators of Effect Sizes Using Analog to ANOVA Tests 
  Subgroup Analysis Moderator Test 
 Studies, k 
ES 
(g) 95% CI Qb 
p-
value 
Study Moderatorsa       
Sample type       
Recruited 51 0.20 0.10 0.29 0.02 0.88 
Referred 13 0.21 0.01 0.42   
Study Location       
North America 19 0.19 0.02 0.35 0.08 0.96 
Outside North America 44 0.21 0.11 0.31   
Type of evaluation       
Efficacy 43 0.15 0.09 0.21 4.05 0.04 
Effectiveness 21 0.07 0.02 0.12   
Comparator condition       
No treatment or waitlist 39 0.26 0.16 0.37 3.72 0.05 
Psychotherapy placebo or active 25 0.09 -0.05 0.23   
Participant Moderatorsb       
Youth ethnicity       
Majority Caucasian sample 25 0.19 0.01 0.37 0.37 0.54 
Majority non-Caucasian 
sample  
3 0.01 -0.54 0.56   
Youth gender       
Majority male (≤ 50% boys) 21 0.24 0.10 0.39 0.65 0.42 
Majority female (>50% girls) 42 0.17 0.07 0.27   
Developmental period       
Childhood (Mage ≤ 12 years) 32 0.16 0.07 0.25 0.78 0.38 
Adolescence (Mage > 12 years) 14 0.24 0.09 0.39   
Focal Anxiety Concern       
Specific Phobia 7 0.41 0.08 0.73 1.72 0.42 
Mixed Anxiety 52 0.18 0.09 0.27   
Social Anxiety 5 0.22 0.03 0.41   
Intervention Moderatorsc       
Level of Intervention       
Treatment 25 0.33 0.22 0.44 28.11 0.001* 
Targeted Prevention 17 0.21 0.12 0.30   
Universal Prevention 17 0.04 -0.01 0.09   
Primary Format       
Individual 9 0.30 0.05 0.55 3.70 0.59 
Group 30 0.17 0.06 0.28   
Digital 11 0.25 0.05 0.44   
ABMt 8 0.11 -0.15 0.37   
Recipient of Intervention       
Child 57 0.20 0.11 0.29 0.02 0.88 
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Parent 6 0.18 -0.08 0.43   
Delivery Setting       
Research 18 0.34 0.15 0.53 2.85 0.24 
Community 35 0.15 0.05 0.26   
Home/Digital 11 0.22 0.02 0.40   
Provider Type       
Professional 42 0.26 0.15 0.37 3.36 0.07 
Non-Professional 22 0.08 0.02 0.13   
Training for Providers       
Required 29 0.16 0.04 0.25 0.02 0.90 
Not required 7 0.14 0.06 0.38   
Supervision for Providers       
Required 27 0.12 0.01 0.23 0.84 0.34 
Not required 15 0.20 0.06 0.35   
Note: Qb = Between group Q-test value (analog-to-ANOVA); Significant Qb value 
indicates moderation effect; * = statistically significant at the family-level p-value 
ascertained from the Holm’s modified Bonferroni correction 
a = Significance threshold for study-level moderator family was ≤ 0.0125 
b = Significance threshold for participant-level moderator family was ≤	0.0125 
c = Significance threshold for participant-level moderator family was ≤	0.008 
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Table 6. Pre to Post Moderators of Effect Sizes Using Analog to ANOVA Tests 
  Subgroup Analysis Moderator 
Test 
 Studies, k 
ES 
(g) 95% CI Qb 
p-
value 
Study Moderators       
Sample type       
Recruited 27 0.25 0.14 0.37 0.46 0.50 
Referred 3 0.08 -0.40 0.56   
Study Location       
North America 19 0.19 0.02 0.35 0.04 0.85 
Outside North America 44 0.21 0.11 0.31   
Type of evaluation       
Efficacy 20 0.30 0.15 0.44 1.41 0.24 
Effectiveness 10 0.16 0.02 0.34   
Comparator condition       
No treatment or waitlist 18 0.32 0.18 0.47 3.50 0.06 
Psychotherapy placebo or active 12 0.11 -0.07 0.29   
Participant Moderators       
Youth ethnicity       
Majority Caucasian sample 8 0.24 0.02 0.47 - - 
Majority non-Caucasian sample  1 - - -   
Youth gender       
Majority male (> 50% boys) 9 0.28 0.09 0.48 0.46 0.50 
Majority female (>50% girls) 20 0.20 0.07 0.34   
Developmental period       
Childhood (Mage < 12 years) 17 0.16 0.06 0.25 4.49 0.03 
Adolescence (Mage > 12 years) 5 0.07 0.12 0.26   
Focal Anxiety Concern       
Specific Phobia 2 0.75 0.13 1.37 3.12 0.21 
Mixed Anxiety 25 0.24 0.12 0.35   
Social Anxiety 3 0.09 -0.31 0.50   
Intervention Moderators       
Level of Intervention       
Treatment 6 0.32 0.01 0.65 0.84 0.66 
Targeted Prevention 15 0.29 0.14 0.44   
Universal Prevention 8 0.19 0.01 0.37   
Primary Format       
Individual 4 0.24 -0.14 0.62 3.21 0.52 
Group 16 0.33 0.17 0.48   
Digital 5 0.11 -0.13 0.35   
ABMt 4 0.08 -0.26 0.42   
Recipient of Intervention       
Child 26 0.23 0.11 0.35 0.06 0.81 
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Parent 3 0.27 -0.07 0.62   
Delivery Setting       
Research 6 0.32 0.00 0.63 0.29 0.86 
Community 20 0.23 0.09 0.36   
Home/Digital 4 0.26 -0.02 0.55   
Provider Type       
Professional 21 0.29 0.15 0.43 1.01 0.31 
Non-Professional 9 0.17 -0.02 0.35   
Training for Providers       
Required 13 0.19 0.07 0.32 0.14 0.71 
Not required 3 0.14 -0.11 0.39   
Supervision for Providers       
Required 8 0.11 0.08 0.30 0.69 0.41 
Not required 9 0.18 0.05 0.31   
Note: Average time of follow-up assessments used in effect size calculations was 8.88 
months (SD = 8.76 months); - denotes less than 2 studies available to meta-analyze; Qb 
= Between group Q-test value (analog-to-ANOVA); Significant Qb value indicates 
moderation effect; * = statistically significant at the family-level p-value ascertained 
from the Holm’s modified Bonferroni correction 
a = Significance threshold for study-level moderator family was ≤ 0.0125 
b = Significance threshold for participant-level moderator family was ≤	0.0125 
c = Significance threshold for participant-level moderator family was ≤	0.008 
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Figure 1. Flowchart for Study Identification, Screening, and Inclusion 
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Figure 2. Minimal EBI Effect Sizes for Pediatric Anxiety by Level of Intervention 
 
 
From Reynolds et al. (2012), the dashed line in the treatment column refers to the 
overall pre to post effect size of 0.70 (UCL: 1.17; LCL: 0.32) resulting from typical 
length treatments for pediatric anxiety whereas the dotted line refers to the lower 
confidence level of the overall effect size (the UCL is not illustrated). The dashed and 
dotted lines in the targeted and universal prevention columns refers to the overall pre to 
post effect size of 0.18 (UCL: 0.23; LCL: 0.13) and lower confidence limit, 
respectively, as reported by Fisak et al. (2011). 
  
Note: Effect sizes reported are between-group 
 
 
Well-Established Effect Size Possibly Efficacious Effect Size
